

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/109290 A2

(51) International Patent Classification⁷: **G01N 33/68**

(21) International Application Number:
PCT/US2004/017234

(22) International Filing Date: 28 May 2004 (28.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/474,488 30 May 2003 (30.05.2003) US
60/475,873 3 June 2003 (03.06.2003) US
60/553,838 17 March 2004 (17.03.2004) US

(71) Applicants (for all designated States except US):
ROSETTA INPHARMATICS LLC [US/US]; 401 Terry
Avenue North, Seattle, WA 98109 (US). **MERCK & CO.,
INC.** [US/US]; P.O. Box 2000, RY 60-30, Rahway, NJ
07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAO, Mao**
[CN/US]; 17630 NE 129th Place, Redmond, WA 98052

(US). **LINSLEY, Peter, S.** [US/US]; 2528 11th Avenue W,
Seattle, WA 98119 (US). **BUSER, Carolyn, A.** [US/US];
227 Fawn Drive, Harleysville, PA 19438 (US). **MAR-
SHALL, Christopher, Gary** [CA/US]; 603 Derstine
Avenue, Lansdale, PA 19446 (US). **KIM, Annette, S.**
[US/US]; 2410 Old Forty Foot Road, Harleysville, PA
19438 (US).


(74) Agent: **BLÖCHLINGER, Karen, B.**; Christensen
O'Connor Johnson Kindness PLLC, 1420 Fifth Avenue,
Suite 2800, Seattle, WA 98101-2347 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: METHODS FOR IDENTIFYING MODULATORS OF KINESIN ACTIVITY





ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

METHODS FOR IDENTIFYING MODULATORS OF KINESIN ACTIVITY

FIELD OF THE INVENTION

The invention relates to methods for identifying modulators of the activity of KIF14 and related proteins, and methods of treating conditions such as cancer using these modulators.

BACKGROUND OF THE INVENTION

Breast cancer is the most common cancer in women and the second most common cause of cancer death in the United States. KIF14 was identified as a gene whose expression was positively correlated with a poor prognostic outcome of breast cancer, as assessed by the time interval to distant metastases in patients without tumor cells in local lymph nodes at diagnosis (van't Veer et al. (2002) *Nature* 415:530-536). KIF14 is a member of the kinesin family (KIF) of proteins. Kinesins are microtubule-dependent molecular motors that use the energy from ATP hydrolysis to move cargo along microtubules. Many kinesins have been shown to play important roles in cell division.

There is a need for methods to identify compounds that will be useful for inhibiting cellular proliferation and treating patients with cellular proliferation disorders, such as breast cancer. In particular, there is a need for methods for identifying modulators of the activity of a target protein such as KIF14, whose expression is associated with poor prognosis in cancer patients. The present invention addresses these needs.

SUMMARY OF THE INVENTION

The sequence of the KIF14 cDNA is provided in SEQ ID NO:1. In a first aspect, the invention provides methods for screening for modulators of a target protein, wherein the target protein comprises a sequence that has more than 80% amino acid sequence identity to KIF14 (SEQ ID NO:2) or the KIF14 motor domain (SEQ ID NO:3). The methods comprise the steps of contacting a target protein with a candidate agent and determining whether the candidate agent modulates the activity of the target protein. Some embodiments provide methods in which (a) the target protein is contacted with the candidate agent at a first concentration and a first level of activity of the target protein is measured; and (b) the target protein is contacted with the candidate agent at a second concentration and a second level of activity of the target protein is measured, wherein a difference between the first level of activity and the second level of activity of the target

protein indicates that the candidate agent modulates the activity of the target protein. In some embodiments, the target protein comprises the amino acid sequence of KIF14 (SEQ ID NO:2). The target protein may also comprise amino acids 356 to 709 encoding the KIF14 motor domain (SEQ ID NO:3) or any fragment of SEQ ID NO:3 having ATPase activity. For example, the target protein may be a protein comprising the sequence between amino acid 342 to amino acid 720 of the KIF14 protein (SEQ ID NO:4), a protein comprising the sequence between amino acid 342 to amino acid 710 of the KIF14 protein (SEQ ID NO:5), a protein comprising the sequence between amino acid 354 to amino acid 720 of the KIF14 protein (SEQ ID NO:6), or a protein comprising the sequence between amino acid 354 to amino acid 710 of the KIF14 protein (SEQ ID NO:7).

The target protein may be contacted with the candidate agent *in vivo* or *in vitro*. For example, the methods may also comprise expressing the target protein in a cell. The assays used for measuring the activity of the target protein include, but are not limited to, ATPase assays, binding assays, microtubule-binding assays, and microtubule-gliding assays, cell proliferation assays, cell viability assays, cell cycle distribution assays, and cell death assays. These assays may use fluorescence, luminescence, radioactivity, or absorbance for determining whether the candidate agent modulates the activity of the target protein. In some embodiments, a high throughput screening assay is used for determining whether the candidate agent modulates the activity of the target protein.

In a second aspect, the invention provides methods of modulating cell proliferation, comprising administering to a cell an effective amount of a modulator of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. The modulators may be administered to cells *in vitro*, such as in tissue culture, or *in vivo*, such as to a subject. In some embodiments, the target protein comprises the amino acid sequence provided in SEQ ID NO:2 or SEQ ID NO:3, or any fragment thereof having ATPase activity. The modulator of the activity of the target protein may be an inhibitor, such as an inhibitor of target protein expression or an inhibitor of microtubule-dependent ATP hydrolysis by the target protein. In some embodiments, the modulator is an RNA inhibitor, for example, a KIF14 RNA inhibitor comprising the sequence provided in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:23. In some embodiments, the modulator is an inhibitor of microtubule-dependent ATP hydrolysis by the target protein. Inhibitors of

microtubule-dependent ATP hydrolysis by the target protein include, but are not limited to, small organic compounds, such as semicarbazones and thiosemicarbazones. For example, the inhibitor may be an aryl thiosemicarbazone.

5 Some embodiments of this aspect of the invention provide methods for treating a subject with a cellular hyperproliferation disorder, such as cancer. These methods comprise administering to a subject with a cellular hyperproliferation disorder, such as breast cancer, a therapeutically effective amount of an inhibitor of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. Some
10 embodiments of this aspect of the invention provide methods of treating a subject with a cellular hyperproliferation disorder by administering therapeutically effective amounts of a known therapeutic agent and an inhibitor of the activity of a target protein to the subject.

In a third aspect, the invention provides methods for identifying candidate
15 subjects for treatment with a modulator of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. These methods comprise the steps of: (a) measuring the level of expression of a target protein in sample cells of a subject and (b) identifying the subject as a candidate subject for treatment with a modulator of
20 the activity of a target protein if the level of expression of the target protein in the sample cells is significantly different than in control cells. In some embodiments, the target protein comprises the amino acid sequence provided in SEQ ID NO:2 or SEQ ID NO:3, or any fragment thereof having ATPase activity. The level of expression of the target protein in sample cells may be determined at the level of mRNA or at the level of protein.
25 The methods may further comprise the step of treating the candidate subject with a modulator of the activity of the target protein.

Some embodiments provide methods for identifying candidate subjects for treatment with an inhibitor of the activity of the a target protein by (a) measuring the level of expression of a target protein in abnormally proliferating cells of a subject and
30 (b) identifying the subject as a candidate subject for treatment with an inhibitor of the activity of a target protein if the level of expression of the target protein in the abnormally proliferating cells is significantly higher than in control cells. The methods may further

comprise the step of treating the candidate subject with an inhibitor of the activity of the target protein.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

FIGURE 1 shows the patterns of gene regulation in various cell lines treated with a panel of growth factors for increasing amounts of time, as described in EXAMPLE 2. Tumor (MCF7, HT29) and normal (HMEC, SKMC) cells were serum-starved and then stimulated with growth factors heregulin, insulin, IGF1, FGF and EGF for 0.5, 2, 6, 18 or 24 hrs. White bars indicate up-regulated genes; black bars indicate down regulated genes. Each row represents cells treated with a different growth factor, with time of treatment increasing in the upward direction. Data were clustered with kinesin sequences present on the hu25k array. The kinesins annotated in LocusLink as having mitotic function are indicated with diamonds; those annotated as transport functions with squares; and one kinesin annotated with both mitotic and transport functions with a circle. The arrow indicates KIF14.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention provides methods for screening for modulators of a target protein. The invention also provides methods for inhibiting cell proliferation and methods of treating a subject with a cellular proliferation disorder by administering an effective amount of an inhibitor of a target protein. Furthermore, the invention provides methods for identifying candidate subjects for treatment with inhibitors of a target protein. In some embodiments of the methods, the target protein is the KIF14 protein (SEQ ID NO:2). In some embodiments, the target protein is a protein comprising a sequence that has more than 80% amino acid sequence similarity to the KIF14 protein (SEQ ID NO:2) or to the motor domain of KIF14 (SEQ ID NO:3).

The expression of the KIF14 transcript (SEQ ID NO:1) was found to be positively correlated with a poor prognostic outcome of breast cancer, as assessed by the time interval to distant metastases in patients without tumor cells in local lymph nodes at diagnosis (van't Veer et al. (2002) *Nature* 415:530-536). The KIF14 gene encodes a protein (SEQ ID NO:2) with a putative kinesin motor domain (MD) (SEQ ID NO:3). As

used herein, the term "motor domain" refers to the domain of a target protein that confers membership in the kinesin superfamily of motor proteins (see, e.g., Vale & Fletterick (1997) *Annu. Rev. Cell Dev. Biol.* 13:745-77). The expression of the KIF14 transcript (SEQ ID NO:1) is elevated in tumor cells, as described in EXAMPLE 1. The pattern of KIF14 expression in cell lines treated with growth factor is similar to that of mitotic kinesins, as described in EXAMPLE 2. In addition, the accumulation of KIF14 mRNA during mitosis as well as the dynamic cellular localization of KIF14 protein during mitosis is similar to that observed for mitotic kinesins, as described in EXAMPLE 3. Moreover, reducing KIF14 expression in cells results in growth inhibition and cell death, as described in EXAMPLE 4. Specifically, reduction of KIF14 expression is associated with aberrant cytokinesis, as described in EXAMPLES 5 and 6. The effect of KIF14 depletion on cytokinesis is more pronounced in tumor cells than in normal cells, as shown in EXAMPLE 6.

In a first aspect, the invention provides methods for screening for modulators of a target protein, wherein the target protein comprises a sequence that has more than 80% amino acid sequence identity to KIF14 (SEQ ID NO:2) or the KIF14 motor domain (SEQ ID NO:3). The methods comprise the steps of contacting a target protein with a candidate agent and determining whether the candidate agent modulates the activity of the target protein.

As used herein, the term "target protein" refers to a protein that has one or more of the biological activities of KIF14, including, but not limited to, microtubule stimulated ATPase activity, as tested, for example, in an ATPase assay. "ATPase activity" refers to the ability to hydrolyze ATP. Biological activity can also be demonstrated in a microtubule gliding assay or a microtubule binding assay. Other biological activities of target proteins may include polymerization/depolymerization (effects on microtubule dynamics), binding to other proteins of the spindle, binding to proteins involved in cell-cycle control, or serving as a substrate to other enzymes, such as kinases or proteases and specific kinesin cellular activities, such as involvement in chromosome segregation. The term "protein" refers to a compound that comprises at least two covalently linked amino acids. The target proteins may be from eukaryotes or prokaryotes, such as from mammals, fungi, bacteria, insects, plants, and viruses.

In addition, the target proteins used in the methods of the invention are proteins with a sequence that has more than 80% amino acid sequence identity (such as more

than 90% sequence identity, more than 95% amino acid sequence identity, or more than 99% sequence identity) to KIF14 (SEQ ID NO:2) or the KIF1414 motor domain (SEQ ID NO:3). The terms "identical" or percent "identity", in the context of two or more amino acid sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.

It is recognized that amino acid positions that are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. The scoring of conservative substitutions can be calculated according to, for example, the algorithm of Meyers & Millers (1988) *Computer Applic. Biol. Sci.* 4:11-17.

A "comparison window" includes reference to a segment of contiguous positions, such as between about 25 and about 600 positions, or between about 50 to 200 positions, or between about 100 and 150 positions, over which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, for example, by a local homology algorithm (Smith & Waterman (1981) *Adv. Appl. Math.* 2:482), by a global alignment algorithm (Needleman & Wunsch (1970) *J. Mol. Biol.* 48:443), by search for similarity methods (Pearson & Lipman (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:2444; Altschul et al. (1997) *Nucl. Acids Res.* 25(17):3389-402), by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and BLAST in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), typically using the default settings, or by manual alignment and visual inspection (see, e.g., *Current Protocols in Molecular Biology* (1994) Ausubel et al., eds.). For example, BLAST protein searches can be performed using the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences that are

more than 80% identical to the amino acid sequence of KIF14 (SEQ ID NO:2) or the KIF14 motor domain (SEQ ID NO:3).

One example of a useful algorithm implementation is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle (1987) *J. Mol. Evol.* 35:351-60. The method used is similar to the method described by Higgins & Sharp (1989) *CABIOS* 5:151-3. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster can then be aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences can be aligned by a simple extension of the pairwise alignment of two individual sequences. A series of such pairwise alignments that includes increasingly dissimilar sequences and clusters of sequences at each iteration produces the final alignment.

The definition of target proteins also include proteins encoded by nucleic acid sequences that hybridize to the sequence encoding KIF14 (SEQ ID NO:1) to form a heteroduplex with a T_m that is within 20°C of that of KIF14 (SEQ ID NO:1) homoduplex. The melting temperature of a DNA duplex is calculated using the formula:

$$T_m = 81.5 + 16.6(\log_{10}[\text{Na}^+] + 0.41(\text{fraction G+C}) - 0.63(\%\text{formamide}) - (600/l))$$

where l is the length of the hybrid in basepairs (Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, page 9.51). This equation applies to the "reversible" T_m that is defined by optical measurement of the hyperchromicity at OD₂₅₇. The melting temperature decreases by 1-1.5°C for every 1% decrease in sequence identity (Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, page 9.51).

Also included within the definition of target proteins of the present invention are amino acid sequence variants of wild-type target proteins. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants may be prepared by site-specific mutagenesis of nucleotides in the DNA encoding the

target protein. Site-specific mutagenesis may be performed using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Variant target protein fragments having up to about 100-150 amino acid residues may be prepared by
5 *in vitro* synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the target protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified
10 properties. Conservative substitution tables providing functionally similar amino acids are well known in the art (Henikoff & Henikoff (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:10915-9).

Amino acid substitutions are typically of single residues. Insertions usually will be on the order of from about 1 to about 20 amino acids, although considerably longer
15 insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases, deletions may be much longer. Substitutions, deletions, and insertions or any combinations thereof may be used to arrive at a final derivative.

Accordingly, in some embodiments of the methods, the target protein comprises the KIF14 protein (SEQ ID NO:2). In other embodiments, the target protein comprises a
20 portion of the KIF14 protein (SEQ ID NO:2) encoding the KIF14 motor domain (SEQ ID NO:3), or fragments thereof that have microtubule-dependent ATPase activity. For example, the target protein may be a protein comprising the sequence between amino acid 342 to amino acid 720 of the KIF14 protein (SEQ ID NO:4). Alternatively, the target protein may be a protein comprising the sequence between amino acid 342 to
25 amino acid 710 of the KIF14 protein (SEQ ID NO:5), a protein comprising the sequence between amino acid 354 to amino acid 720 of the KIF14 protein (SEQ ID NO:6), or a protein comprising the sequence between amino acid 354 to amino acid 710 of the KIF14 protein (SEQ ID NO:7).

The target proteins used in the methods of the invention are typically expressed
30 using an expression system and purified. An expression system includes expression vectors and host cells. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, expression vectors include transcriptional and translational regulatory nucleic acid

operably linked to the nucleic acid encoding the target protein. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Operably linked DNA sequences may be contiguous or non-contiguous. Linking may be accomplished by ligation, for example by ligation at convenient restriction sites. If such sites do not exist, blunt-end ligation and/or synthetic oligonucleotide adaptors or linkers may be used. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the target protein; for example, transcriptional and translational regulatory nucleic acid sequences from *Bacillus* are preferably used to express the target protein in *Bacillus*. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art.

An expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to a sequence in the host cell genome, and preferably two homologous sequences that flank the expression

construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

5 In addition, an expression vector typically contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

10 The target proteins used in the present invention may be produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a target protein, under the appropriate conditions to induce or cause expression of the target protein. The conditions appropriate for target protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art using routine experimentation. For example, the growth and proliferation of the host cell may be optimized for the use of constitutive promoters in the expression vector, and appropriate growth conditions for induction are provided for use
15 of an inducible promoter. In addition, in some embodiments, the timing of the harvest is important, for example, when using baculoviral systems.

Appropriate host cells include yeast, bacteria, archaeobacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Drosophila melanogaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*,
20 Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, THP1 cell line (a macrophage cell line), and human cells and cell lines.

Accordingly, in some embodiments, the target proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. Promoters from viral genes are frequently used in mammalian
25 expression systems, because the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop
30 codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived from SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, are well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, 5 encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In some embodiments, the target proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid 10 promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal 15 peptide sequence that provides for secretion of the target protein in bacteria. The target protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The expression vector may also include an epitope tag providing for affinity purification of the target protein. The bacterial expression vector may also 20 include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes that render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. These components 25 are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others. The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others. An exemplary method for expressing KIF14 30 motor domain proteins using a bacterial expression system is described in EXAMPLE 7.

Target proteins may also be produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art. In addition, target proteins may be produced in yeast cells. Yeast

expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillermondii* and *P. pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*.

5 The target protein may also be made as a fusion protein, using techniques well known in the art. For example, the target protein may be made as a fusion protein to increase expression or to link it with a tag polypeptide that provides an epitope to which an anti-tag antibody can selectively bind. Exemplary tags include the myc epitope and 6-histidine. The epitope tag is generally placed at the amino-or carboxyl-terminus of the
10 target protein. The presence of such epitope-tagged forms of a target protein can be detected using an antibody against the tag polypeptide. Thus, the epitope tag enables the target proteins to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine
15 (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field et al. (1988) *Mol. Cell. Biol.* 8:2159-65); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al. (1985) *Mol. Cell. Biol.* 5:3610-6); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al. (1990) *Prot. Eng.* 3(6):547-53). Other tag polypeptides include the Flag-peptide (Hopp et al. (1988) *BioTechnol.* 6:1204-10); the KT3 epitope peptide (Martin et al. (1992) *Science* 255:192-4); tubulin epitope peptide (Skinner et al. (1991) *J. Biol. Chem.* 266:15163-6); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:6393-7).

25 The target proteins used in the methods of the invention may be labeled. As used herein, the term "labeled" refers to the attachment of at least one element, isotope or chemical compound to enable the detection of the target protein. A label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means. Thus, labels may be isotopic labels; which may be radioactive or heavy isotopes, immune labels, which may be antibodies or antigens; and
30 colored or fluorescent dyes. The labels may be incorporated into the target proteins at any position. For example, the label should be capable of producing, either directly or indirectly, a detectable signal. The detectable moiety may be a radioisotope, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or

luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for attaching the label to the target protein may be employed.

Covalent modifications of target proteins are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a target protein with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of a target protein. Derivatization with bifunctional agents is useful, for instance, for crosslinking a target protein to a water-insoluble support matrix or surface for use in screening assays. Commonly used crosslinking agents include, but are not limited to, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

The target protein may be purified or isolated after expression. The terms "isolated" "purified" or "biologically pure" refer to material that is substantially or essentially free from components which normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. The term "purified" denotes that a protein gives rise to essentially one band in an electrophoretic gel. For example, it means that the protein is at least 85% pure, such as at least 95% pure, such as at least 99% pure.

Target proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the target protein may be purified using a standard anti-KIF14 antibody column (see, e.g., KIF14 antibody ab3746, Abcam). Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. Suitable purification techniques are standard in the art (see, e.g., Scopes (1982) Protein Purification, Springer-Verlag, NY). The degree of purification necessary will vary depending on the use of the target protein. In some

instances no purification may be necessary. Exemplary protocols for purifying target proteins for use in the methods of the invention are provided in EXAMPLES 7 and 8.

In the first step of the methods of this aspect of the invention, the target protein is contacted with a candidate agent. Candidate agents may encompass numerous chemical classes. Typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2500 daltons. Small molecules are further defined herein as having a molecular weight of between 150 daltons and 2000 daltons, such as less than 1500, or less than 1200, or less than 1000, or less than 750, or less than 500 daltons. Thus, a small molecule may have a molecular weight of about 100 to 200 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof.

Candidate agents may be obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, and amidification, to produce structural analogs.

The second step of the methods comprises determining whether the candidate agent modulates the activity of the target protein. As used herein, the term "modulates the activity of the target protein" refers to any change in the activity of the target protein, such as a decrease or an increase in the activity. Typically, samples or assays are treated with a candidate agent at a test and control concentration. The control concentration may be zero. If there is a change in target protein activity between the two concentrations, this

change indicates that the candidate agent modulates the activity of the target protein. Thus, some embodiments provide methods in which (a) the target protein is contacted with the candidate agent at a first concentration and a first level of activity of the target protein is measured; and (b) the target protein is contacted with the candidate agent at a second concentration and a second level of activity of the target protein is measured, wherein a difference between the first level of activity and the second level of activity of the target protein indicates that the candidate agent modulates the activity of the target protein. A difference in activity, which can be an increase or decrease, may be a change of at least 20% to 50%, such as at least 50% to 75%, such as at least 75% to 100%, such as at least 150% to 200%, such as at least 200% to 1000%, compared to a control. Additionally, a difference in activity can be indicated by a change in binding specificity or substrate.

The activity of the target protein may be measured using *in vitro* assays and purified or partially purified proteins. The activity of the target protein may also be measured using *in vivo* assays by expressing the target protein in cells. The assays used may be multi-time-point (kinetic) assays, with at least two data points. In the case of multiple measurements, the absolute rate of the protein activity may be determined. As will be appreciated by those in the art, the components in the assay may be added in buffers and reagents to assay target protein activity and give optimal signals. Moreover, to allow kinetic measurements the incubation periods are typically optimized to give adequate detection signals over the background.

Assays for measuring the activity of the target protein include measuring ATPase activity, microtubule-gliding, microtubule-polymerization/depolymerizing activity (effects on microtubule dynamics), and binding activities, such as microtubule-binding, binding to proteins of the spindle, binding to proteins involved in cell cycle control, or binding of nucleotide analogs (see, e.g., Kodama et al. (1986) *J. Biochem.* 99:1465-72; Stewart et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:5209-13; Lombillo et al. (1995) *J. Cell Biol.* 128:107-15; Vale et al. (1985) *Cell* 42:39-50). In the case that the target protein used has another specific activity, such as involvement in mitosis or axonal transport, specific assays for those activities can be used. Exemplary assays are described below.

In some embodiments, the assay used to measure the activity of the target protein comprises measuring ATPase activity, as described in EXAMPLES 7-9. Thus, ADP or

phosphate is used as a readout for target protein activity. In these embodiments, the target protein is contacted with the candidate agents under conditions that allow production of ADP or phosphate by the target protein and the effect of the candidate agents on the production of ADP or phosphate by the target protein is measured.

5 Conditions that allow production of ADP or phosphate by the target protein are conditions under which the reaction which produces ADP or phosphate would normally occur in the absence of a candidate agent that modulates the activity of the target protein.

The production of ADP or phosphate may be measured enzymatically. There are a number of enzymatic reactions known in the art which use ADP as a substrate. For example, kinase reactions, such as pyruvate kinase reactions are well known and allow the regeneration of ATP (see, e.g., Greengard (1956) *Nature* 178:632-4). The level of activity of the enzymatic reaction may be determined directly. For example, in a pyruvate kinase reaction, pyruvate or ATP can be measured by conventional methods known in the art. The level of activity of the enzymatic reaction which uses ADP as a

10 substrate may also be measured indirectly by being coupled to another reaction, such as a lactate dehydrogenase reaction. Measurement of enzymatic reactions by coupling is known in the art (see, e.g., Greengard (1956) *Nature* 178:632-4).

Furthermore, there are a number of reactions which utilize phosphate, for example a purine nucleoside phosphorylase reaction. This reaction may be measured directly by conventional methods known in the art. The reaction may also be measured indirectly by coupling it to another reaction, such as a purine analog cleavage reaction under conditions which normally allow the cleavage of the purine analog (see, e.g., Webb (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:4884-7; Rieger et al. (1997) *Anal. Biochem.* 246:86-95; Banik et al. (1990) *Biochem. J.* 266:611-4. Alternatively, xanthine oxidase may be used in

20 conjunction with purine nucleoside phosphorylase to couple phosphate production to a change in the absorbance of a substrate for xanthine oxidase (Ungerer et al. (1993) *Clin. Chim. Acta.* 223:149-57).

The production of ADP or phosphate may be detected non-enzymatically, for example by binding or reacting the ADP or phosphate with a detectable compound. For example, phosphomolybdate based assays, which involve conversion of free phosphate to a phosphomolybdate complex, may be used (Fiske et al. (1925) *J. Biol. Chem.* 66:375-400). One method of quantifying the phosphomolybdate is with malachite green. Alternatively, a fluorescently labeled form of a phosphate-binding protein, such as the

30

E. coli phosphate-binding protein, can be used to measure phosphate by a shift in its fluorescence.

In a preferred embodiment, detection of the assay is done using a detectable label, such as an isotopic label (radioactive or heavy isotopes), magnetic, electrical, thermal; colored or luminescent dyes, enzymes, and particles such as magnetic particles. The dyes may be chromophores, phosphors, or fluorescent dyes. Typically, fluorescent signals provide a good signal-to-noise ratio for detection. Suitable dyes for use in the invention include, but are not limited to, fluorescent lanthanide complexes, including those of Europium and Terbium, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malachite green, stilbene, Lucifer Yellow, Cascade Blue, Texas Red, and derivatives thereof, and other (see also Richard P. Haugland, *Molecular Probes Handbook*, 6th ed.). In some embodiments, phosphate production is measured using the dye Quinaldine Red, which absorbs light at a wavelength of 540 nm when bound to inorganic phosphate, as described in EXAMPLES 7-9.

The invention provides methods of screening candidate agents for the ability to serve as modulators of target protein activity. For example, high throughput screening (HTS) systems may be used. HTS systems may include the use of robotic systems and offer the advantage that many samples can be processed in a short period of time. HTS systems are commercially available (see, e.g., Zymark Corp., Hopkinton, Mass.; Air Technical Industries, Mentor, Ohio; Beckman Instruments, Inc., Fullerton, Calif.; Precision Systems, Inc., Natick, Mass.). HTS systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems may be customized and provide high throughput, rapid start up, and a high degree of flexibility.

A plurality of assay mixtures may be run in parallel with different candidate agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, that is, a candidate agent concentration of zero or below the level of detection. However, any concentration can be used as the control for comparative purposes.

HTS methods generally involve providing a library containing a large number of candidate agents. For example, combinatorial chemical libraries may be screened in one or more assays, as described herein, to identify those library members (particular

chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified may serve as conventional lead compounds or can themselves be used as potential or actual therapeutic compounds.

For example, candidate agents may be assayed in highly parallel fashion by using multiwell plates and by placing the candidate agents either individually in wells or testing them in mixtures. Assay components, such as for example, target proteins, protein filaments, coupling enzymes and substrates, and ATP can then be added to the wells and the absorbance or fluorescence of each well of the plate can be measured by a plate reader. A candidate agent which modulates the function of the target protein is identified by an increase or decrease in the rate of ATP hydrolysis compared to a control assay in the absence of that candidate agent.

In some embodiments of the methods of the invention, target protein activity is identified by an ATP hydrolysis assay as described above. However, it is understood that target activity can be identified by a number of assays. Such assays include microtubule gliding, depolymerization/polymerization, and any activity which requires both binding and ATPase activity. Generally motility assays involve immobilizing one component of the system (e.g., the target protein or the microtubule) and then detecting movement, or change thereof, of the other component. Thus, for example, the target protein may be immobilized (e.g., attached to a solid substrate) and the movements of microtubules may be monitored. Typically the molecule that is to be detected is labeled (e.g., with a fluorescent label) to facilitate detection. Methods of performing motility assays are well known to those of skill in the art (see, e.g., Hall et al. (1996) *Biophys. J.* 71:3467-76, Turner et al. (1996) *Anal. Biochem.* 242(1):20-5; Gittes et al. (1996) *Biophys. J.* 70(1):418-29; Shirakawa et al. (1995) *J. Exp. Biol.* 198:1809-15; Winkelmann et al. (1995) *Biophys. J.* 68:2444-53; Winkelmann et al. (1995) *Biophys. J.* 68:72S).

Moreover, if the protein used has another specific activity, such as involvement in mitosis or axonal transport, specific assays for those activities can be utilized. For example, target protein activity may be examined by determining modulation of target protein activity *in vitro* using cultured cells. The cells may endogenously express the target protein, or they may be engineered to express a target protein, for example by introducing a vector comprising a nucleic acid sequence encoding the target protein, as described above. The cells are treated with a candidate agent and the effect of the

candidate agent on the cells is then determined either directly or by examining relevant surrogate markers.

In some embodiments, cells containing target proteins are used in candidate agent screening assays by evaluating the effect of candidate agents on cellular proliferation. Useful cell types include normal cells and cells with abnormal proliferative rates, such as tumor cells. Methods of assessing cellular proliferation are known in the art and include growth and viability assays using cultured cells. In such assays, cell populations are monitored for growth and or viability, often over time and comparing samples incubated with various concentrations of the candidate agent or without the candidate agent. Cell number may be quantified using agents such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and alamarBlue™, which are converted to colored or fluorescent compounds in the presence of metabolically active cells. Alternatively, dyes that bind to cellular protein such as sulforhodamine B (SRB) or crystal violet may be used to quantify cell number. Cells may also be directly counted using a particle counter, such as a Coulter Counter manufactured by Beckman Coulter, or counted using a microscope to observe cells on a hemocytometer. Typically, cells counted using the hemocytometer are observed in a solution of trypan blue to distinguish viable from dead cells. Other methods of quantifying cell number are known to those skilled in the art. These assays may be performed on any of the cells, including those in a state of necrosis.

Moreover, apoptosis can be determined by methods known in the art. For example, markers for apoptosis are known, and TUNEL (TdT-mediated dUTP-fluorescein nick end labeling) kits can be bought commercially (e.g., Boehringer Mannheim, Cat. No. 168795). Other markers for apoptosis include caspase activity, as described in EXAMPLE 4.

The cell proliferation assays are evaluated in the presence or absence or previous or subsequent exposure to physiological signals, for example hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e., cell-cell contacts). In addition, the cell proliferation assays may be evaluated at different stages of the cell cycle process to assess characteristics such as mitotic spindle morphology and cell cycle distribution (see, e.g., Mayer et al. (1999) *Science* 286:971-4)

Exemplary methods for assessing the effect of candidate agents on the growth and viability of cells expressing KIF14 are described in EXAMPLES 4 and 9. Cells with high proliferation rates, such as cancer cells, generally express high levels of KIF14, as described in EXAMPLE 1. Conversely, reducing KIF14 expression using RNA
5 interference results in growth inhibition and cell death, as described in EXAMPLE 4. Thus, candidate agents that modulate KIF14 activity may result in a change in cell growth or viability of KIF14-expressing cells, as described in EXAMPLE 9.

Exemplary methods for assessing the effect of candidate agents on characteristics such as mitotic spindle morphology and cell cycle distribution of cells expressing KIF14
10 is described in EXAMPLES 5 and 6. Reduction of KIF14 expression using RNA interference results in aberrant cytokineses and the formation of binucleate cells, as described in EXAMPLES 5 and 6. Thus, candidate agents that modulate KIF14 activity may result in a cytokinetic change in KIF14-expressing cells with no or minimal effects in cells that do not express KIF14.

15 In some embodiments, candidate agents that modulate the activity of a target protein may be identified by using competitive binding assays. In these assays, the competitor is a binding moiety known to bind to the target protein, such as an antibody, peptide, binding partner, or ligand.

Competitive screening assays may be done by combining the target protein and a
20 candidate agent in a first sample. A second sample comprises that candidate agent, the target protein and a compound that is known to bind to the target protein. These assays may be performed in either the presence or absence of microtubules. The binding of the candidate agent is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the
25 target protein and potentially modulating its activity. That is, if the binding of the candidate agent is different in the second sample relative to the first sample, the candidate agent is capable of binding to the target protein.

The candidate agent may be labeled. Either the candidate agent, or the competitor, or both, is added first to the target protein for a time sufficient to allow
30 binding. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4°C and 40°C. Incubation periods may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component

is then added, and the presence or absence of the labeled component is followed, to indicate binding.

The competitor may be added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to the target protein and thus is capable of binding to, and potentially modulating, the activity of the target protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.

Alternatively, the candidate agent may be added first, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to the target protein with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to the target protein.

In a second aspect, the invention provides methods for modulating cell proliferation. The methods comprise administering to a cell an effective amount of a modulator of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. The target proteins used in the methods of this aspect of the invention are as described above for the methods of the first aspect of the invention. Modulators of the activity of the target protein are agents whose administration results in a change in the activity of the target protein, as defined above. For example, a modulator of the activity of a target protein may inhibit or stimulate the activity of the target protein. Modulators that may be used in this aspect of the invention may be identified by screening candidate agents, as described above for the first aspect of the invention.

Typically, administration of modulators that inhibit the activity of the target protein have the effect of inhibiting cell growth or causing cell death, as described in EXAMPLES 4 and 9. Administration of such inhibitory modulators are useful, for example, for treating conditions in which there is hyperproliferation of cells, such as cancer, restenosis, autoimmune disease, arthritis, graft rejection, inflammatory bowel disease, or proliferation induced after medical procedures.

Conversely, modulators that increase the activity of the target protein have the effect of stimulating cell division, as described in EXAMPLE 1. Administration of such

stimulatory modulators are useful, for example, for treating conditions in which there is hypoproliferation of cells or in which enhancement of cell proliferation is desired, such as during wound healing or stem cell expansion.

Some embodiments provide methods of modulating cell proliferation by administering an inhibitor of the activity of the target protein. The inhibitor may be an RNA inhibitor. The term "RNA inhibitor" refers to an inhibitory RNA that silences expression of the target protein by RNA interference (McManus & Sharp (2002) *Nat. Rev. Genet.* 3:737-47; Hannon (2002) *Nature* 418:244-51; Paddison & Hannon (2002) *Cancer Cell* 2:17-23). RNA interference is conserved throughout evolution, from *C. elegans* to humans, and is believed to function in protecting cells from invasion by RNA viruses. When a cell is infected by a dsRNA virus, the dsRNA is recognized and targeted for cleavage by an RNaseIII-type enzyme termed Dicer. The Dicer enzyme "dices" the RNA into short duplexes of 21 nucleotides, termed short-interfering RNAs or siRNAs, composed of 19 nucleotides of perfectly paired ribonucleotides with two unpaired nucleotides on the 3' end of each strand. These short duplexes associate with a multiprotein complex termed RISC, and direct this complex to mRNA transcripts with sequence similarity to the siRNA. As a result, nucleases present in the RISC complex cleave the mRNA transcript, thereby abolishing expression of the gene product. In the case of viral infection, this mechanism would result in destruction of viral transcripts, thus preventing viral synthesis. Since the siRNAs are double-stranded, either strand has the potential to associate with RISC and direct silencing of transcripts with sequence similarity.

Recently, it was determined that gene silencing could be induced by presenting the cell with the siRNA, mimicking the product of Dicer cleavage (Elbashir et al. (2001) *Nature* 411:494-8; Elbashir et al. (2001) *Genes Dev.* 15:188-200). Synthetic siRNA duplexes maintain the ability to associate with RISC and direct silencing of mRNA transcripts, thus providing researchers with a powerful tool for gene silencing in mammalian cells. Yet another method to introduce the dsRNA for gene silencing is shRNA, for short hairpin RNA (Paddison et al. (2002) *Genes Dev.* 16:948-58; Brummelkamp et al. (2002) *Science* 296:550-3; Sui et al. (2002) *Proc. Natl. Acad. Sci. U.S.A.* 99:5515-20). In this case, a desired siRNA sequence is expressed from a plasmid (or virus) as an inverted repeat with an intervening loop sequence to form a hairpin structure. The resulting RNA transcript containing the hairpin is subsequently processed

by Dicer to produce siRNAs for silencing. Plasmid-based shRNAs can be expressed stably in cells, allowing long-term gene silencing in cells, or even in animals (McCaffrey et al. (2002) *Nature* 418:38-9; Xia et al. (2002) *Nat. Biotech.* 20:1006-10; Lewis et al. (2002) *Nat. Genetics* 32:107-8; Robinson et al. (2003) *Nat. Genetics* 33:401-6; Tiscornia et al. (2003) *Proc. Natl. Acad. Sci. U.S.A.* 100:1844-8). RNA interference has been
5 successful used therapeutically to protect mice from fulminant hepatitis (Song et al. (2003) *Nat. Medicine* 9:347-51).

Thus, in some embodiments of the invention, cell proliferation is inhibited by administering KIF14 siRNAs, as described in EXAMPLES 4-6. The KIF14 siRNA may
10 comprise the sequence provided in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:23.

In some embodiments, cell proliferation is inhibited by administering an inhibitor of microtubule-dependent ATP hydrolysis by the target protein. Exemplary inhibitors include small molecule organic compounds, such as semicarbazones and thiosemicarbazones. For example, the inhibitor may be an aryl thiosemicarbazone, as
15 described in EXAMPLE 9. Exemplary aryl thiosemicarbazone inhibitors include, but are not limited to, 1,1'-biphenyl-4-carbaldehyde thiosemicarbazone (compound 1), 4-isopropylbenzaldehyde thiosemicarbazone (compound 2; see, e.g., U.S. Patent No. 3,849,575), 4-cyclohexylbenzaldehyde thiosemicarbazone (compound 3), and 4-isopropyl-3-nitrobenzaldehyde thiosemicarbazone (compound 4; see, e.g., Saripinar et al.
20 (1996) *Arzneimittel-Forschung* 46(II):824-8).

The modulators may be administered to a cell *in vitro*, such as by administering them to cells in tissue culture. Modulators may be administered to cells *in vitro* using conventional protocols in the art, including transfection, lipofection, microinjection, and others described above. The modulators may also be administered to cells *in vivo*, by
25 administering the modulators to a subject. The term "subject" refers to a living organism, such as a plant or an animal. Exemplary subjects are mammals, such as humans. For example, the subject may be a human cancer patient. Administration of modulators to a subject is accomplished by any effective route, for example, locally, systemically, parenterally, or orally. For example, an inhibitory modulator may be injected directly
30 into a tumor, or into a blood vessel that supplies blood to the tumor. Methods of parenteral delivery include topical, intra-arterial, subcutaneous, intramedullary, intravenous, or intranasal administration.

The amount of the modulator actually administered in the methods of this aspect of the invention is an effective amount. The term "effective amount" refers to the amount needed to produce a substantial effect. Effective amounts of the modulators administered in the methods of this aspect of the invention will generally range up to the maximally tolerated dosage, but may vary widely. The precise amounts employed will vary depending on the compound, route of administration, physical condition of the subject, and other factors. The daily dosage may be administered as a single dosage or may be divided into multiple doses for administration.

Effective amounts of the modulator may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. The animal model is also typically used to determine a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans or other mammals. The determination of an effective dose is well within the capability of those skilled in the art. Thus, the amount actually administered will be dependent upon the individual to which treatment is to be applied, and will preferably be an optimized amount such that the desired effect is achieved without significant side-effects.

Therapeutic efficacy and possible toxicity of the modulators can be determined by standard pharmaceutical procedures, in cell cultures or experimental animals (e.g., ED₅₀, the dose therapeutically effective in 50% of the population; and LD₅₀, the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio ED₅₀/LD₅₀. Modulatory compounds that exhibit large therapeutic indices are particularly suitable in the practice of the methods of the invention. The data obtained from cell culture assays and animal studies may be used in formulating a range of dosage for use in humans or other mammals. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage typically varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. Thus, optimal amounts will vary with the method of administration, and will generally be in accordance with the amounts of conventional medicaments administered in the same or a similar form.

The modulators may be formulated into a composition that additionally contains suitable pharmaceutically acceptable carriers, including excipients and other compounds

that facilitate administration of the modulator to a mammalian subject. Further details on techniques for formulation and administration may be found in the latest edition of *Remington's Pharmaceutical Sciences* (Maack Publishing Co, Easton PA).

Compositions for oral administration may be formulated using pharmaceutically acceptable carriers well known in the art, in dosages suitable for oral administration. Such carriers enable the compositions containing inhibitors to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc., suitable for ingestion by a subject. Compositions for oral use may be formulated, for example, in combination with a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable excipients include carbohydrate or protein fillers. These include, but are not limited to, sugars, including lactose, sucrose, mannitol, or sorbitol, starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins, such as gelatin and collagen. If desired, disintegrating or solubilising agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound (i.e., dosage).

Modulators for oral administration may be formulated, for example, as push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules may contain modulators mixed with filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, modulators may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Compositions for parenteral administration include aqueous solutions of one or more modulators. For injection, the modulators may be formulated in aqueous solutions,

such as in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the modulators may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the modulators to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are typically used in the formulation. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone, dimethylacetamide, dimethyl-formamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface-active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.

The amounts of each of these various types of additives will be readily apparent to those skilled in the art, optimal amounts being the same as in other, known formulations designed for the same type of administration. Stratum corneum penetration enhancers, for example, will typically be included at levels within the range of about 0.1% to about 15%.

Compositions containing the modulators may be manufactured in a manner similar to that known in the art (e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes). The compositions may also be modified to provide appropriate release characteristics, e.g., sustained release or targeted release, by conventional means (e.g., coating).

Compositions containing the modulators may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After compositions formulated to contain modulators and an acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for use.

Some embodiments of this aspect of the invention provide methods of treating a subject with a cellular hyperproliferation disorder by administering a therapeutically effective amount of an inhibitor of the activity of a target protein to the subject, wherein the target protein comprising a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3.

The term "cellular hyperproliferation disorders" refers to any condition in which there is excessive cellular proliferation, such as cancer, restenosis, autoimmune disease, arthritis, graft rejection, inflammatory bowel disease, or proliferation induced after medical procedures. In some embodiments, the cellular hyperproliferation disorder is cancer, including, but not limited to brain cancer, head and neck cancer, esophageal cancer, breast cancer, lung cancer, stomach cancer, pancreatic cancer, liver cancer, colorectal cancer, bladder cancer, renal cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, melanoma, multiple melanoma, leukemia, and lymphoma. The inhibitor administered in this embodiment of the methods may be an inhibitory RNA, such as a KIF14 siRNA. The KIF14 siRNA may comprise the sequence provided in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:23. The inhibitor administered may also be an inhibitor of microtubule-dependent ATP hydrolysis by the target protein. Exemplary inhibitors include small molecule organic compounds, such as semicarbazones and thiosemicarbazones. For example, the inhibitor may be an aryl thiosemicarbazone, such as 1,1'-biphenyl-4-carbaldehyde thiosemicarbazone (compound 1), 4-isopropylbenzaldehyde thiosemicarbazone (compound 2; see, e.g., U.S. Patent No. 3,849,575), 4-cyclohexylbenzaldehyde thiosemicarbazone (compound 3), or 4-isopropyl-3-nitrobenzaldehyde thiosemicarbazone (compound 4; see, e.g., Saripinar et al. (1996) *Arzneimittel-Forschung* 46(II):824-8), as described in EXAMPLE 9. Effective amounts and useful routes of administration are described above.

Some embodiments of this aspect of the invention provide methods of treating a subject with a cellular hyperproliferation disorder by administering therapeutically effective amounts of a known therapeutic agent and an inhibitor of the activity of a target protein to the subject, wherein the target protein comprising a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. As used herein, the term "known therapeutic agent" includes, but is not limited to, anti-

cancer agents and radiation therapy. Thus, the target protein inhibitors of the invention, such as the inhibitors described above, may be administered in combination with known anti-cancer agents. Examples of such agents can be found in *Cancer Principles and Practice of Oncology* (Devita & Hellman, eds.), 6th ed. (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Such anti-cancer agents include, but are not limited to, the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic/cytostatic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors and other angiogenesis inhibitors, inhibitors of cell proliferation and survival signaling, agents that interfere with cell cycle checkpoints. HIV protease inhibitors, reverse transcriptase inhibitors, and other angiogenesis inhibitors.

"Estrogen receptor modulators" refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyloxy)phenyl]-2H-1-benzopyran-3-yl]-phenyl)-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.

"Androgen receptor modulators" refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.

"Retinoid receptor modulators" refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl) retinamide, and N-4-carboxyphenyl retinamide.

"Cytotoxic/cytostatic agents" refer to compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-

stabilizing agents, inhibitors of mitotic kinesins, inhibitors of kinases involved in mitotic progression, antimetabolites; biological response modifiers; hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal antibody targeted therapeutic agents, topoisomerase inhibitors, proteosome inhibitors and ubiquitin ligase inhibitors.

Examples of cytotoxic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro (2-methyl-pyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3-aziridiny-4-methylsulphonyl-daunorubicin (see WO 00/50032).

An example of a hypoxia activatable compound is tirapazamine.

Examples of proteosome inhibitors include, but are not limited to, lactacystin and MLN-341 (Velcade).

Examples of microtubule inhibitors/microtubule-stabilising agents include, but are not limited to, paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, the epothilones (see for example U.S. Patent Nos. 6,284,781 and 6,288,237) and BMS188797. In some embodiments, the epothilones are not included in the microtubule inhibitors/microtubule-stabilising agents.

Examples of topoisomerase inhibitors include, but are not limited to, topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)

propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]-indolizino [1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S) camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro (3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c] quinolin-7-one, and dimesna.

Examples of inhibitors of mitotic kinesins, and in particular the human mitotic kinesin KSP, are described in PCT Publications WO 01/30768 and WO 01/98278, and pending U.S. Serial Nos. 60/338,779 (filed December 6, 2001), 60/338,344 (filed December 6, 2001), 60/338,383 (filed December 6, 2001), 60/338,380 (filed December 6, 2001), 60/338,379 (filed December 6, 2001) and WO 03/39460. In an embodiment inhibitors of mitotic kinesins include, but are not limited to inhibitors of KSP, inhibitors of MKLP1, inhibitors of CENP-E, inhibitors of MCAK and inhibitors of Rab6-KIFL.

"Inhibitors of kinases involved in mitotic progression" include, but are not limited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases (PLK) (in particular inhibitors of PLK-1), inhibitors of bub-1 and inhibitors of bub-R1.


"Antiproliferative agents" includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-

tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and trastuzumab.

Examples of monoclonal antibody targeted therapeutic agents include those therapeutic agents which have cytotoxic agents or radioisotopes attached to a cancer cell specific or target cell specific monoclonal antibody. Examples include Bexxar.

10 "HMG-CoA reductase inhibitors" refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Patent No. 4,231,938, at column 6, and WO 84/02131, at pages 30-33. The terms "HMG-CoA reductase inhibitor" and
15 "inhibitor of HMG-CoA reductase" have the same meaning when used herein.

Examples of HMG-CoA reductase inhibitors that may be used include but are not limited to lovastatin (MEVACOR®; see U.S. Patent Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Patent Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Patent Nos. 4,346,227, 4,537,859,
20 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL®; see U.S. Patent Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896), atorvastatin (LIPITOR®; see U.S. Patent Nos. 5,273,995, 4,681,893, 5,489,691 and 5,342,952) and cerivastatin (also known as rivastatin and BAYCHOL®; see US Patent No. 5,177,080). The structural formulas of these and additional HMG-CoA
25 reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", *Chemistry & Industry*, pp. 85-89 (5 February 1996) and U.S. Patent Nos. 4,782,084 and 4,885,314. The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as
30 salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention. An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I and II.



In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein. In some embodiments, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and in further embodiments, simvastatin. Herein, the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenz-imidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate,

panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.

Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

"Prenyl-protein transferase inhibitor" refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (\pm)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (-)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolymethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolymethyl]-5-[2-(ethanesulfonyl)methyl]-2-piperazinone, 5(S)-n-Butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolymethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolymethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-hydroxymethyl-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-[3-(2-oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 18,19-dihydro-19-oxo-5H,17H-6,10:12,16-dimetheno-1H-imidazo[4,3-c][1,11,4]dioxazacyclopentadecine-9-carbonitrile, (\pm)-19,20-dihydro-19-oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzimidazo[4,3-k][1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5H,17H-18,21-ethano-6,10:12,16-dimetheno-22H-imidazo[3,4-h][1,8,11,14]oxatriazacycloeicosine-9-carbonitrile, and (\pm)-19,20-dihydro-

3-methyl-19-oxo-5*H*-18,21-ethano-12,14-etheno-6,10-metheno-22*H*-benzo
[*d*]imidazo[4,3-*k*][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.

Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701,
5 WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917,
10 WO 95/12612, WO 95/12572, WO 95/10514, U.S. Patent No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Patent No. 5,571,792, WO 96/17861, WO 96/33159, WO 96/34850,
15 WO 96/34851, WO 96/30017, WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359.

20 For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis see *Eur. J. of Cancer* 35(9):1394-1401 (1999).

"Angiogenesis inhibitors" refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase
25 receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- α , interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib and rofecoxib (*Proc. Natl. Acad. Sci. U.S.A.* 89:7384 (1992); *J. Natl. Cancer. Inst.* 69:475
30 (1982); *Arch. Ophthalmol.* 108:573 (1990); *Anat. Rec.* 238:68 (1994); *FEBS Lett.* 372:83 (1995); *Clin. Orthop.* 313:76 (1995); *J. Mol. Endocrinol.* 16:107 (1996); *Jpn. J. Pharmacol.* 75:105 (1997); *Cancer Res.* 57:1625 (1997); *Cell* 93:705 (1998); *Intl. J. Mol.*

Med. 2:715 (1998); *J. Biol. Chem.* 274:9116 (1999)), steroidal anti-inflammatories (such as corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, betamethasone), carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl-fumagillol, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see Fernandez et al. (1985) *J. Lab. Clin. Med.* 105:141-5), and antibodies to VEGF (see *Nature Biotechnol.* 17:963-8 (1999); Kim et al. (1993) *Nature* 362:841-4; WO 00/44777; and WO 00/61186).

Other therapeutic agents that modulate or inhibit angiogenesis and may also be used in combination with target protein inhibitors include agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in *Clin. Chem. La. Med.* 38:679-92 (2000)). Examples of such agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin (see *Thromb. Haemost.* 80:10-23 (1998)), low molecular weight heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see *Thrombosis Res.* 101:329-54 (2001)). TAFIa inhibitors have been described in WO 03/13526 and U.S. Serial No. 60/349,925 (filed January 18, 2002).

"Agents that interfere with cell cycle checkpoints" refer to compounds that inhibit protein kinases that transduce cell cycle checkpoint signals, thereby sensitizing the cancer cell to DNA damaging agents. Such agents include inhibitors of ATR, ATM, the Chk1 and Chk2 kinases and cdk and cdc kinase inhibitors and are specifically exemplified by 7-hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS-387032.


"Inhibitors of cell proliferation and survival signalling pathway" refer to compounds that inhibit signal transduction cascades downstream of cell surface receptors. Such agents include inhibitors of serine/threonine kinases, including but not limited to inhibitors of Akt such as described in WO 02/083064, WO 02/083139, WO 02/083140 and WO 02/083138), inhibitors of Raf kinase (for example BAY-43-9006), inhibitors of MEK (for example CI-1040 and PD-098059), inhibitors of mTOR (for example Wyeth CCI-779), and inhibitors of PI3K (for example LY294002).

The combinations with NSAID's are directed to the use of NSAIDs which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an IC₅₀ for the inhibition of COX-2 of 1 micromolar or less as measured by cell or microsomal assays.


The invention also encompasses combinations with NSAIDs which are selective COX-2 inhibitors. For purposes of this specification NSAIDs which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC_{50} for COX-2 over IC_{50} for COX-1 evaluated by cell or microsomal assays. Such compounds include, but are not limited to those disclosed in U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, U.S. Patent No. 6,001,843, issued December 14, 1999, U.S. Patent No. 6,020,343, issued February 1, 2000, U.S. Patent No. 5,409,944, issued April 25, 1995, U.S. Patent No. 5,436,265, issued July 25, 1995, U.S. Patent No. 5,536,752, issued July 16, 1996, U.S. Patent No. 5,550,142, issued August 27, 1996, U.S. Patent No. 5,604,260, issued February 18, 1997, U.S. Patent No. 5,698,584, issued December 16, 1997, U.S. Patent No. 5,710,140, issued January 20, 1998, WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992, U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790, issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995, U.S. Patent No. 5,633,272, issued May 27, 1997, and U.S. Patent No. 5,932,598, issued August 3, 1999, all of which are hereby incorporated by reference.

Inhibitors of COX-2 that are useful in the instant method of treatment include:

3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone; and




5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine;




or a pharmaceutically acceptable salt thereof.


General and specific synthetic procedures for the preparation of the COX-2 inhibitor compounds described above are found in U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, and U.S. Patent No. 6,001,843, issued December 14, 1999, all of which are herein incorporated by reference.

Compounds that have been described as specific inhibitors of COX-2 and are therefore useful in the present invention include, but are not limited to, the following:



10





or a pharmaceutically acceptable salt thereof.

Compounds that are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992, U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790, issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995, U.S. Patent No. 5,633,272, issued May 27, 1997, and U.S. Patent No. 5,932,598, issued August 3, 1999.

Compounds that are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, U.S. Patent No. 6,001,843, issued December 14, 1999, U.S. Patent No. 6,020,343, issued February 1, 2000, U.S. Patent No. 5,409,944, issued April 25, 1995, U.S. Patent No. 5,436,265, issued July 25, 1995, U.S. Patent No. 5,536,752, issued July 16, 1996, U.S. Patent No. 5,550,142, issued August 27, 1996, U.S. Patent No. 5,604,260, issued February 18, 1997, U.S. Patent No. 5,698,584, issued December 16, 1997, and U.S. Patent No. 5,710,140, issued January 20, 1998.

Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-

pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

As used above, "integrin blockers" refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha_v\beta_3$ integrin, to
 5 compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha_v\beta_5$ integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the $\alpha_v\beta_3$ integrin and the $\alpha_v\beta_5$ integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of
 10 the $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins. The term also refers to antagonists of any combination of $\alpha_v\beta_3$, $\alpha_v\beta_5$, $\alpha_v\beta_6$, $\alpha_v\beta_8$, $\alpha_1\beta_1$, $\alpha_2\beta_1$, $\alpha_5\beta_1$, $\alpha_6\beta_1$ and $\alpha_6\beta_4$ integrins.

Some specific examples of tyrosine kinase inhibitors include N-(trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-5-yl)
 15 methylidenyl]indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, SH268, genistein,
 20 STI571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD121974.

Combinations with compounds other than anti-cancer compounds are also
 25 encompassed in the methods of the invention. For example, combinations of the instantly claimed compounds with PPAR- γ (i.e., PPAR-gamma) agonists and PPAR- δ (i.e., PPAR-delta) agonists are useful in the treatment of certain malignancies. PPAR- γ and PPAR- δ are the nuclear peroxisome proliferator-activated receptors γ and δ . The expression of PPAR- γ on endothelial cells and its involvement in angiogenesis has been reported in the
 30 literature (see *J. Cardiovasc. Pharmacol.* (1998) 31:909-13; *J. Biol. Chem.* (1999) 274:9116-21; *Invest. Ophthalmol Vis. Sci.* (2000) 41:2309-17). More recently, PPAR- γ agonists have been shown to inhibit the angiogenic response to VEGF *in vitro*; both troglitazone and rosiglitazone maleate inhibit the development of retinal

neovascularization in mice (*Arch. Ophthalmol.* (2001) 119:709-17). Examples of PPAR- γ agonists and PPAR- γ/α agonists include, but are not limited to, thiazolidinediones (such as DRF2725, CS-011, troglitazone, rosiglitazone, and pioglitazone), fenofibrate, gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, JTT-501, MCC-555, GW2331, GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, GI262570, PNU182716, DRF552926, 2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionic acid (disclosed in USSN 09/782,856), and 2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy) phenoxy)propoxy)-2-ethylchromane-2-carboxylic acid (disclosed in U.S. Serial Nos. 60/235,708 and 60/244,697).

In some embodiments of the invention, target protein inhibitors are used in combination with gene therapy for the treatment of cancer. For an overview of genetic strategies to treating cancer see Hall et al. (1997) *Am J Hum Genet* 61:785-9. and Kufe et al. (2000) *Cancer Medicine*, 5th ed, pp 876-89, BC Decker, Hamilton). Gene therapy can be used to deliver any tumor suppressing gene. Examples of such genes include, but are not limited to, p53, which can be delivered via recombinant virus-mediated gene transfer (see, e.g., U.S. Patent No. 6,069,134), a uPA/uPAR antagonist ("Adenovirus-Mediated Delivery of a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice," *Gene Therapy* 5(8):1105-13 (1998)), and interferon gamma (*J Immunol.* 164:217-22 (2000)).

Target protein inhibitors may also be administered in combination with an inhibitor of inherent multidrug resistance (MDR), in particular MDR associated with high levels of expression of transporter proteins. Such MDR inhibitors include inhibitors of p-glycoprotein (P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833 (valspodar).

Target protein inhibitors may be employed in conjunction with anti-emetic agents to treat nausea or emesis, including acute, delayed, late-phase, and anticipatory emesis, which may result from the use of a compound of the present invention, alone or with radiation therapy. For the prevention or treatment of emesis, a compound of the present invention may be used in conjunction with other anti-emetic agents, especially neurokinin-1 receptor antagonists, 5HT₃ receptor antagonists, such as ondansetron, granisetron, tropisetron, and zatisetron, GABAB receptor agonists, such as baclofen, a corticosteroid such as Decadron (dexamethasone), Kenalog, Aristocort, Nasalide, Preferid, Benecorten or others such as disclosed in U.S. Patent Nos. 2,789,118,

2,990,401, 3,048,581, 3,126,375, 3,929,768, 3,996,359, 3,928,326 and 3,749,712, an
antidopaminergic, such as the phenothiazines (for example prochlorperazine,
fluphenazine, thioridazine and mesoridazine), metoclopramide or dronabinol. For the
treatment or prevention of emesis that may result upon administration of the target
5 protein inhibitors, conjunctive therapy with an anti-emesis agent may be selected from a
neurokinin-1 receptor antagonist, a 5HT₃ receptor antagonist, and a corticosteroid.

Neurokinin-1 receptor antagonists of use in conjunction with the target protein
inhibitors of the present invention are fully described, for example, in U.S. Patent
Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926,
10 5,496,833, 5,637,699, 5,719,147; European Patent Publication Nos. EP 0 360 390,
0 394 989, 0 428 434, 0 429 366, 0 430 771, 0 436 334, 0 443 132, 0 482 539, 0 498 069,
0 499 313, 0 512 901, 0 512 902, 0 514 273, 0 514 274, 0 514 275, 0 514 276, 0 515 681,
0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478,
0 558 156, 0 577 394, 0 585 913, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629,
15 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 709 375, 0 709 376,
0 714 891, 0 723 959, 0 733 632 and 0 776 893; PCT International Patent Publication
Nos. WO 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151,
92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 92/22569, 93/00330, 93/00331,
93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14084,
20 93/14113, 93/18023, 93/19064, 93/21155, 93/21181, 93/23380, 93/24465, 94/00440,
94/01402, 94/02461, 94/02595, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625,
94/07843, 94/08997, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639,
94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740,
94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549,
25 95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129, 95/19344,
95/20575, 95/21819, 95/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687,
95/33744, 96/05181, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939,
96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214,
96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362,
30 97/18206, 97/19084, 97/19942 and 97/21702; and in British Patent Publication
Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168,
2 293 169, and 2 302 689. The preparation of such compounds is fully described in the
aforementioned patents and publications, which are incorporated herein by reference.

In some embodiments, the neurokinin-1 receptor antagonist for use in conjunction with the compounds of the present invention is selected from: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine, or a pharmaceutically acceptable salt thereof, which is
5 described in U.S. Patent No. 5,719,147.

Target protein inhibitors may also be administered with an agent useful in the treatment of anemia. Such an anemia treatment agent is, for example, a continuous erythropoiesis receptor activator (such as epoetin alfa).

Target protein inhibitors may also be administered with an agent useful in the
10 treatment of neutropenia. Such a neutropenia treatment agent is, for example, a hematopoietic growth factor which regulates the production and function of neutrophils such as a human granulocyte colony stimulating factor, (G-CSF). Examples of a G-CSF include filgrastim.

Target protein inhibitors may also be administered with an immunologic-
15 enhancing drug, such as levamisole, isoprinosine and Zadaxin.

In a third aspect, the invention provides methods for identifying candidate subjects for treatment with a modulator of the activity of a target protein. The methods comprise the steps of: (a) measuring the level of expression of a target protein in sample cells from a subject, wherein the target protein comprises a sequence that has more than
20 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3; and (b) identifying the subject as a candidate subject for treatment with a modulator of the activity of the target protein if the level of expression of the target protein in the sample cells is significantly different than in control cells.

In the first step, the level of expression of a target protein in sample cells of the
25 subject is measured. As used herein, the term "sample cells" refers to cells from any clinically relevant tissue sample, such as a tumor biopsy or fine needle aspirate, or a sample of bodily fluid, such as blood, plasma, serum, lymph, ascitic fluid, cystic fluid, urine, or nipple exudate. The sample may be taken from a human or from a non-human subject. The target proteins used in the methods of this aspect of the invention are as
30 described above for the methods of the first aspect of the invention.

The level of expression of the target protein may be determined by any means known in the art. The expression level may be determined by isolating and measuring the amount of nucleic acid transcribed from the gene encoding the target protein.

Alternatively, or additionally, the amount of target proteins translated may be determined. For example, the level of expression of the target protein may be determined by isolating RNA from the sample and hybridizing it to nucleic acid probes specific for the DNA or RNA equivalent of the transcript of the gene encoding the target protein. Useful techniques for measuring mRNA levels include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis, RNase protection, and hybridization to microarrays. The level of expression of the target protein may also be assessed at the protein level. Useful techniques for measuring protein levels include, but are not limited to, standard immunoassays using antibodies to the target protein, mass spectroscopy assays, antibody microarrays, and 2D gel electrophoresis assays. Exemplary methods for measuring expression levels of a target protein is provided in EXAMPLES 1, 2, and 6.

In the second step, the subject is identified as a candidate subject for treatment with a modulator of the activity of a target protein if the level of expression of the target protein in the sample cells is significantly different than in control cells. The term "control cells" refers to reference cells that are expressing a desirable level of the target protein. The control cells may be, but are not necessarily, cells from the same subject from which the sample cells are obtained. Control cells may be obtained from the same tissue from which the sample cells are obtained. The control cells may also be cells from the same tissue type but from a different subject. Control cells may also include hypothetical cells, for example, imaginary cells that represent an average of target protein expression levels in multiple subjects or that represent an idealized level of expression of the target protein.

The comparison of the levels of expression in the sample cells and the control cells may be made using conventional methods in the art. For example, comparison of expression levels may be accomplished visually or by means of a densitometer. Generally, methods for comparing levels of gene expression provide an estimate of the statistical significance of the difference in expression levels. For example, repeated measurements of individual samples may be used to estimate the mean and standard error of a measured expression level. According to the methods of this aspect of the invention, if the difference in expression levels in control cells and abnormally proliferating cells is determined to be statistically significant, the subject is identified as a candidate subject for treatment with a modulator of the activity of the target protein. In some embodiments, the methods of this aspect of the invention further comprise treating the

candidate subject by administering a modulator of the activity of the target protein, as described above.

In some embodiments, the methods identify candidate subjects for treatment with an inhibitor of the activity of a target protein. However, the methods of this aspect of the invention are also applicable for identifying candidate subjects for treatment with a modulator that stimulates the activity of the target protein. The methods for identifying candidate subjects for treatment with an inhibitor of the activity of a target protein comprise the steps of: (a) measuring the level of expression of the target protein in abnormally proliferating cells of a subject, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3; and (b) identifying the subject as a candidate subject for treatment with inhibitors of the activity of a target protein if the level of expression of the target protein in the abnormally proliferating cells is significantly higher than in control cells. According to this embodiment, the sample cells are abnormally proliferating cells. Typically, the control cells used in this embodiment are cells that are not proliferating abnormally. In some embodiments, the methods of this aspect of the invention further comprise treating the candidate subject by administering an inhibitor of the activity of the target protein, as described above.

The present invention also provides kits for screening for modulators of target proteins comprising a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3. These kits may contain materials and reagents for screening for modulators of the target proteins and instructions describing how to perform the screen. For example, the kits may include a biologically active target protein, reaction tubes, and instructions for testing the activity of the target protein. The kits may be tailored to the use of a specific assay for the activity of the target protein. Thus, the kits may be tailored for ATPase assays, microtubule-binding assays, microtubule-gliding assays, or cell growth and viability assays.

Examples provided are intended to assist in a further understanding of the invention and illustrate the best mode now contemplated for practicing the invention. Particular materials employed, species and conditions are intended to be illustrative of the invention and not limiting the reasonable scope thereof.

EXAMPLE 1

This Example describes the KIF14 expression levels in normal and tumor cells.

KIF14 mRNA expression levels were assessed in two normal cell lines, human mammary epithelial cells HMEC (Cambrex Corporation (Clonetics), Cat. No. CC-2551) and human skeletal muscle cells SKMC (Cambrex Corporation, East Rutherford, NJ (BioWhittaker), Cat. No. CC-2561), and two tumor cell lines, colorectal cancer cell line HT-29 (American Type Culture Collection (ATCC), Cat. No. HTB-38) and breast cancer cell line MCF-7 (ATCC, Cat. No. HTB-22). RNA from these cell lines was harvested by following the standard QIAshredder (Qiagen, Cat. No. 79656) homogenization and Qiagen RNeasy protocol (Qiagen, Cat. No. 74106) with an RNase-free DNase step (Qiagen, Cat. No. 7925). Preparation of labeled copy RNA for hybridization to custom made human hu25k microarrays (Agilent Technologies, Inc., Palo Alto, CA), hybridization conditions, and subsequent data processing are as previously described (van't Veer et al. (2002) *Nature* 415:530-536).

Results: The level of expression of KIF14 mRNA was between about 4 and about 6.6 times higher in the tumor cell lines than in normal cells, as shown in Table 1.

Table 1. KIF14 mRNA Expression in Normal and Tumor Cells

Relative KIF14 mRNA Expression Levels	
Cells	Relative-Fold Intensity
SKMC	1.0
HMEC	1.3
HT-29	4.0
MCF7	6.6

To measure the KIF14 mRNA expression in a panel of different human tissues and tumor cell lines, 29 oligonucleotide probes from locations throughout the KIF14 transcript sequence (SEQ ID NO:1) were generated and placed on a microarray. RNA from 68 tissues/cell lines was amplified using a full-length amplification protocol, labeled with either Cy3 or Cy5 dyes, and was hybridized to the microarray, as previously described in Hughes et al. (2001) *Nature Biotechnol.* 19:342-347 and van't Veer et al. (2002) *Nature* 415:530-536. mRNA expression in each tissue was calculated as the exponential of the average of the probe natural-log intensities, after background

subtraction and dye-normalization. Error estimates represent a combination of modeled probe measurement error and the difference between probes. KIF14 was generally found to be expressed at high levels in tumor cell lines, and at lower levels in human tissues, as shown in Table 2.

5

Table 2. KIF14 mRNA Expression in Human Tissues and Tumor Cell Lines

Tissue	Exp.	Err.	Tissue	Exp.	Err.
Lung carcinoma (A549)	3903	623	Brain	104	32
Leukemia-chronic myelogenous (K562)	3126	524	Brain-corpora callosa	102	31
Leukemia-lymphoblastic (MOLT-4)	1971	386	Kidney	102	29
Colorectal adenocarcinoma (SW480)	1860	342	Thyroid	100	28
Leukemia promyelocytic (HL-60)	1859	303	Brain-postcentral gyrus	98	35
HeLa	1676	271	Trachea	98	27
Lymphoma-Burkitt's (Daudi)	1536	375	Liver	94	25
Salivary gland	1184	202	Lung	91	32
Melanoma (G361)	1177	212	Spinal cord	91	27
Bone marrow	920	174	Brain-nucleus accumbens	88	33
Liver-fetal	875	212	Epididymus	85	26
Lymphoma-Burkitt's (Raji)	863	138	Adrenal cortex	84	23
Testes	615	112	Brain-amygdala	83	31
Colon-transverse	538	100	Thymus-normal	77	25
Tonsil	465	82	Brain-cerebellum	76	24
Colon-descending	433	79	Brain-hippocampus	75	29
Ileum	355	100	Brain-thalamus	72	23
Retina	352	78	Prostate	68	27
Bladder	333	86	Pancreas	66	29
Lung-fetal	306	65	Brain-caudate nucleus	62	28
Liver-left lobe	265	67	Brain-cerebral cortex	51	27
Kidney-fetal	262	66	Tongue	50	25
Duodenum	260	57	Heart	35	15

Tissue	Exp.	Err.	Tissue	Exp.	Err.
Stomach	252	52	Skeletal muscle	35	12
Placenta	234	50	Brain-medulla oblongata	31	19
Spinal cord-fetal	207	51	Brain-paracentral gyrus	30	17
Brain-fetal	200	47	Adrenal gland	28	15
Lymph node	185	46	Adipose tissue	24	12
Jejunum	175	56	Lung-upper right lobe	13	8
Ileocecum	154	33	Brain-hypothalamus	12	8
Uterus-corpus	147	46	Brain-frontal lobe	10	5
Uterus	135	37	Brain-temporal lobe	8	5
Spleen	133	31	Brain-putamen	7	5
Adrenal medulla	121	30	Dorsal root ganglion	4	3

Exp. = Expression

Err. = Error Estimate

EXAMPLE 2

5 This Example describes the similarity of the KIF14 mRNA expression pattern in cell lines treated with growth factors to the mRNA expression pattern of mitotic kinesins.

Cell lines MCF-7, HT-29, SKMC, and HMEC, described in EXAMPLE 1, were used. Fifty-six 10 cm plates were seeded with the each cell line to given a density of 70-80% confluence on the first day of the experiment. The cells were serum starved by the aspiration of the 10% FBS/DMEM and the addition of 0.2% FBS/DMEM (charcoal stripped serum). After 24 hours of serum starvation at 37°C, 5 sets of 5 plates were treated with 100 ng/mL of EGF (Upstate Biotechnology, Cat. No. 01-407), 100 ng/mL of β -FGF (Promega, Cat. No. G507A), 100 ng/mL of IGF-1 (Sigma, Cat. No. I 3769), 100 ng/mL of insulin (Sigma, Cat. No. I 2767), and 30 ng/mL of heregulin (NeoMarkers, Cat. No. RP-318-P1AX). Growth factors were resuspended (where applicable) and stored according to the manufacturers instructions. Five sets of 5 plates were correspondingly treated with 0.2% FBS/DMEM (charcoal stripped serum) as a control solution. An additional 6 plates were treated with one of the 5 growth factors or the control. Control plates were done in tandem with their matched treated sample. These latter 6 plates were lysed after 15 minutes for standard Western blotting of

phosphorylated Akt and MAPK to verify that the stimulation had occurred. The remaining plates were incubated for a fixed amount of time in treated and control pairs (30 minutes, 2 hours, 6 hours, 18 hours, and 24 hours) prior to harvesting the RNA following the standard QIAshredder (Qiagen, Cat. No. 79656) homogenization and
5 Qiagen RNeasy protocol (Qiagen, Cat. No. 74106) with an RNase-free DNase step (Qiagen, Cat. No. 7925). Preparation of labeled copy RNA for hybridization to custom made human hu25k microarrays (Agilent Technologies, Inc., Palo Alto, CA), hybridization conditions, and subsequent data processing are as previously described (van't Veer et al. (2002) *Nature* 415:530-536).

10 *Results:* The mRNA expression pattern in cell lines treated with growth factors was different from that of neuronal kinesins but similar to that of nine known mitotic cyclins, CENP-E, KIF4A, MPOHOPH1, hklp2, KNSL6, RAB6KIFL, KNSL5, KNSL4, and KNSL1, as shown in FIGURE 1.

EXAMPLE 3

15 This Example describes the accumulation of KIF14 mRNA and the dynamic cellular localization of KIF14 protein during mitosis.

Transcript accumulation during mitosis is a defining characteristic of mitotic kinesins (Yen et al. (1992) *Nature* 359(6395):53609; Hill et al. (2000) *EMBO J.* 19(21):5711-9). In addition, cellular localization studies have been instrumental in
20 elucidating the function of mitotic cyclins (Yen et al. (1992) *Nature* 359(6395):53609; Hill et al. (2000) *EMBO J.* 19(21):5711-9; Matulienė et al. (2002) *Mol. Biol. Cell.* 13(6):1832-45; Abaza et al. (2003) *J. Biol. Chem.* 278(3):27844-52). Immunofluorescence microscopy was used to visualize the localization of KIF14 protein throughout the cell cycle and microarray profiling was used to analyze the accumulation
25 of KIF14 mRNA in synchronized cells.

Thymidine cell synchronization: HCT116 cells were seeded in 10 cm plates at 1.5×10^6 cells per plate and grown overnight. The original media was aspirated and 10 mls of fresh, filtered media containing 2 mM thymidine (Sigma, cat. no. T-1895, lot No. 28H0393) was added to each plate in order to block cells at G1/S. Cells were
30 incubated at 37°C for 15-16 hrs. Thymidine containing media was aspirated and cells were released from the thymidine block with 2 x 5 ml washes in PBS followed by addition of 10 mls of media containing 24 microM deoxycytidine. Cells were incubated at 37°C for 10 hrs followed by media aspiration, a 5 ml PBS wash and repeat of the G1/S

block by addition of 10 mls of 2 mM thymidine containing media. After 15 hrs of thymidine block, the cells were washed and put into deoxycytidine media which was then $t=0$ for the time course. Samples were collected for FACS, and RNA extraction at 2 hr intervals from $t=0$ to 24 hrs with one additional point at 36 hrs.

5 *Molecular profiling of synchronized HCT116 cells:* For each 10 cm plate, at each designated timepoint, the culture media was completely aspirated and cells were lysed in RLT buffer (Qiagen, Inc. (Valencia, CA), RNeasy kit) containing 1% BME. Cells were scraped and the lysate pipetted to mix and reduce clumps. Cell lysates were homogenized using QIA shredder spin columns and total cellular RNA was isolated using the Rneasy
10 mini kit (Qiagen). RNA amplification, labeling, and hybridization to hu25K ink-jet DNA microarrays was carried out as previously described (Hughes et al. (2001) *Nat. Biotechnol.* 19:342-7; van't Veer et al. (2002) *Nature* 415:530-6).

KIF14 transcripts accumulated in cells progressing through G2/M. The cell cycle dependent regulation of KIF14 expression mirrored that of the known mitotic kinesin,
15 CENPE. These observations lend strong support to the hypothesis that KIF14 functions as a mitotic kinesin.

Immunofluorescence Microscopy: HeLa-S3 cells cultured on glass chamber well slides were fixed and permeabilized for 15 minutes in immunohistochemical buffer containing 100 mM PIPES (pH 6.8), 10 mM EGTA, 1 mM $MgCl_2$, 0.2% Triton X-100,
20 4% formaldehyde (Kapoor et al. (2000) *J. Cell. Biol.* 150(5):975-88). Following fixation, cells were washed 2 times with TBST (see EXAMPLE 5) and incubated with primary antibody for 2 hours at 37°C. Rabbit anti-KIF14 polyclonal antibody was obtained from Abcam, Inc. (ab3746) and used at a 1:500 dilution. Anti-alpha tubulin monoclonal antibody (clone DM1A0) was obtained from SIGMA and used at a 1:500 dilution. Cells
25 were washed 2 times in TBST and primary antibody binding was detected using Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes) and Alexa Fluor 594 goat anti-mouse IgG (Molecular Probes) both used at a 1:250 dilution. Incubation with secondary antibodies was carried out at room temperature for 1 hour followed by 3 washes in TBST supplemented with 10 micrograms/ml Hoechst in order to stain DNA. Slides were
30 mounted with Fluoromount G (Southern Biotech) and visualized directly on a Deltavision v3.5 deconvolution microscope (Applied Precision, Inc.) using DAPI, FITC, and RD-TR-PE filter sets for blue, green, and red, respectively.

KIF14 was dispersed diffusely within the cytoplasm in interphase cells, but in prophase cells it was localized to the centrosomes and their associated microtubules. In metaphase cells, KIF14 was located at the spindle poles and along spindle microtubules. In anaphase cells, KIF14 was found in the spindle midzone, whereas in telophase cells it was more concentrated and co-localized with the midbody matrix and contractile ring. KIF14 was also found localized in extracellular ring-like structures associated with tubulin, reminiscent of contractile rings after completion of cellular abscission. The subcellular localization of KIF14 suggests a role for this protein in cytokinesis. In contrast, KLP38B, the *Drosophila* KIF14 ortholog (Molina et al. (1997) *J. Cell. Biol.* 139(6):1361-71), co-localized with condensed chromatin, suggesting it functions during chromosome segregation.

EXAMPLE 4

This Example describes that transfection of KIF14 siRNA results in the cell growth inhibition and cell death.

Transfection of siRNA: siRNA transfection was used to lower (knockdown) the levels of KIF14 mRNA in order to determine the loss-of-function phenotype of KIF14. One day prior to transfection, 100 microliters of cervical cancer HeLa cells (ATCC, Cat. No. CCL-2), colorectal cancer HCT116 cells (ATCC, Cat. No. CCL-247), or melanoma A2058 cells (ATCC, Cat. No. CRL-1147) grown in DMEM/10% fetal bovine serum (Invitrogen, Carlsbad, CA) to approximately 90% confluency were seeded in a 96-well tissue culture plate (Corning, Corning, NY) at 1500 cells/well. For each transfection 85 microliters of OptiMEM® (Invitrogen) was mixed with 5 microliter of siRNA (Dharmacon, Denver) from a 20 micromolar stock. Two KIF14 siRNA sequences were used:

KIF14-4476: 5' AAACUGGGAGGCUACUUACdTdT 3' (SEQ ID NO:8); and
KIF14-5128: 5' CUCACAUUGUCCACCAGGAdTdT 3' (SEQ ID NO:9).

As a control, luciferase siRNA (5' CGUACGCGGAAUACUUCGAdTdT 3', SEQ ID NO:10) was transfected into each of the three different cell lines. For each transfection 5 microliter OptiMEM® was mixed with 5 microliter Oligofectamine™ reagent (Invitrogen) and incubated 5 minutes at room temperature. The 10 microliter OptiMEM®/Oligofectamine™ mixture was dispensed into each tube with the OptiMEM®/siRNA mixture, mixed and incubated 15-20 minutes at room temperature.

10 microliter of the transfection mixture was aliquoted into each well of the 96-well plate and incubated for 4 hours at 37°C and 5% CO₂. After 4 hours, 100 microliter/well of DMEM/10% fetal bovine serum was added and the plates were incubated at 37°C and 5% CO₂ for 72 hours.

5 *alamarBlue*TM Assay for Cell Growth: The *alamarBlue*TM assay is a measure of cellular respiration and is used as a measure of live cell number. The internal environment of the proliferating cell is more reduced than that of non-proliferating cells. Specifically, the ratios of NADPH/NADP, FADH/FAD, FMNH/FMN, and NADH/NAF increase during proliferation. *alamarBlue*TM can be reduced by these metabolic intermediates and, therefore, can be used to monitor cell proliferation.

10 72 hours after transfection with siRNAs, the *alamarBlue*TM assay was performed to determine whether KIF14 siRNA transfection results in reduced cell growth and/or increased cell death. 72 hours after transfection the medium was removed from the wells and replaced with 100 microliter/well DMEM/10% Fetal Bovine Serum (Invitrogen) containing 10% (vol/vol) *alamarBlue*TM reagent (Biosource International Inc., Camarillo, CA) and 0.001 volumes of 1M Hepes buffer tissue culture reagent (Invitrogen). The plates were incubated 2 hours at 37°C and the plate was read at 570 and 600 nm wavelengths on the SpectraMax plus plate reader (Molecular Devices, Sunnyvale, CA) using Softmax Pro 3.1.2 software (Molecular Devices).

20 The *alamarBlue*TM reduction was calculated as percent reduced using the equation:

$$\text{Percent Reduced} = \frac{(\epsilon_{\text{ox}} \lambda_2) (A \lambda_1) - (\epsilon_{\text{ox}} \lambda_1) (A \lambda_2) \times 100}{(\epsilon_{\text{red}} \lambda_1) (A' \lambda_2) - (\epsilon_{\text{red}} \lambda_2) (A' \lambda_1)}$$

where:

25 $\lambda_1 = 570 \text{ nm}$

$\lambda_2 = 600 \text{ nm}$

$(\epsilon_{\text{red}} \lambda_1) = 155,677$ (Molar extinction coefficient of reduced *alamarBlue*TM at 570 nm)

30 $(\epsilon_{\text{red}} \lambda_2) = 14,652$ (Molar extinction coefficient of reduced *alamarBlue*TM at 600 nm)

$(\epsilon_{ox} \lambda_1) = 80,586$ (Molar extinction coefficient of oxidized alamarBlue™ at 570 nm)

$(\epsilon_{ox} \lambda_2) = 117,216$ (Molar extinction coefficient of oxidized alamarBlue™ at 600 nm)

5 $(A \lambda_1)$ = Absorbance of test wells at 570 nm

$(A \lambda_2)$ = Absorbance of test wells at 600 nm

$(A' \lambda_1)$ = Absorbance of negative control wells which contain medium plus alamarBlue™ but to which no cells have been added at 570 nm.

$(A' \lambda_2)$ = Absorbance of negative control wells which contain medium plus

10 alamarBlue™ but to which no cells have been added at 600 nm.

The percent reduced of the wells containing no medium was subtracted from the percent reduced of the wells containing samples to determine the percent reduced above background. The percent reduced for wells transfected with KIF14 siRNAs were compared to luciferase siRNA-transfected wells. The number calculated for percent reduced for luciferase siRNA-transfected wells was considered to be 100%.

Caspase Activity Measurement: Caspase activity is an indicator of cell death. To measure caspase activity in control and KIF14 siRNA-transfected cells, HeLa cells were seeded at a density of 2000 cells/well in a 96-well black wall clear bottomed tissue culture treated Costar Plate (Costar, Cat. No. 3603) in 100 microliters of DMEM + 10% FBS (with no antibiotics added). All 37°C incubations were performed in a humidified 5% CO₂ incubator. After overnight incubation at 37°C, each well was treated with a transfection mixture to generate a final concentration of 100 nM oligo duplex (Dharmacon, A4 preparation), with 0.5 microliter Oligofectamine™ (Invitrogen, Cat. No. 12252-011), in a total of 10 microliters of Optimem®, which had been allowed to sit 15-20 minutes at ambient temperature prior to addition. After 4-16 hours at 37°C, an additional 90 microliters of warmed media was added. Cells were incubated with the transfection mixture at 37°C for a total of 48 hours. The plates were then spun in a Beckman centrifuge (rotor JS-4.2) at 1200 rpm for 10 minutes at 4°C prior to the aspiration of the media and addition of 40 microliters of lysis buffer (from the ApoAlert kit, Clontech - Fluorescent detection Caspase 3 kit, Cat. No. K2026-2) to each well. The plates were incubated for 20 minutes at 4°C prior to the addition of 10 microliters of a

substrate reaction stock solution. This stock is a solution of 20 microliters of 10 mM DEVD-afc (from Biosource, Cat. No. 77-935, 25 mg, - add DMSO to 10 mM), 20 microliters of 1 M DTT (final concentration about 6 mM), and 760 microliters of 5X Buffer. The 5x Buffer is composed of 250 mM Tris-HCl, 50 mM NaCl, 5 mM MgCl₂,
 5 mM DTT, 5 mM EDTA, and 25% Glycerol. The plates were covered with adhesive foil and incubated overnight at 37°C. Plates were read on a Gemini SpectroMax at excitation 400 nm, emission 505 nm.

Results: There was significant growth inhibition of all three cell types after transfection of either of the two KIF14 siRNA, compared to luciferase siRNA-transfected control cells as shown in Table 3.

Table 3. Growth Inhibition by KIF14 siRNA

siRNA Cells	Mean (%)	Standard Deviation
Luciferase siRNA (SEQ ID NO:10) Control Cells	100	
KIF 4476 (SEQ ID NO:8) HeLa Cells	26.0	2.4
KIF 5128 (SEQ ID NO:9) HeLa Cells	39.4	6.7
KIF 4476 (SEQ ID NO:8) HCT116 Cells	45.5	7.4
KIF 5128 (SEQ ID NO:9) HCT116 Cells	61.7	1.9
KIF 4478 (SEQ ID NO:8) A2058 Cells	33.9	8.9
KIF 5128 (SEQ ID NO:9) A2058 Cells	61.7	10.6

There was a significant induction of caspase activity in KIF siRNA-treated HeLa cells compared to luciferase siRNA-treated HeLa cells, as shown in Table 4. The relative

amount of caspase activity in KIF siRNA-treated HeLa cells suggests that the growth inhibition observed in the alamarBlue TM assay is due, at least in part, to cell death.

Table 4. Induction of Caspase Activity by KIF siRNA

5

siRNA/HeLa Cells	Mean	Standard Deviation
Luciferase/Control Cells	1.0	0.005
KIF14-4476 (SEQ ID NO:8)	5.7	0.4
KIF14-5128 (SEQ ID NO:9)	2.1	0.2

EXAMPLE 5

This Example describes that transfection of KIF14 siRNA results in aberrant cytokinesis and/or apoptosis in HeLa cells.

10 *Cell Morphology Immunofluorescence Methods:* HeLa cells were seeded at a density of 2000 cells/ well in a 96-well black wall clear bottomed tissue culture treated Costar Plate (Costar Cat, Cat. No. 3603) in 100 microliters of DMEM + 10% FBS (with no antibiotics added). After overnight incubation at 37°C, each well was treated with a transfection mixture to generate a final concentration of 100 nM oligo duplex

15 (Dharmacon, A4 preparation), 0.5 microliter OligofectamineTM (Invitrogen, Cat No. 12252-011), in a total of 10 microliters Optimem®, which had been allowed to sit for 15-20 minutes at ambient temperature prior to addition. As a control, HeLa cells were mock-transfected with OligofectamineTM alone. After 4-16h at 37°C, an additional 90 microliters of warmed media was added. Cells were incubated for a designated

20 number of hours (24, 48 or 72h) with the transfection mixture at 37°C. The media was aspirated from the plates prior to their submersion in a vat of -20°C methanol. After 10 minutes at -20°C, the methanol was removed and 100 microliters of a pre-made mixture of the reagents was added. This mixture was composed of 10 ml TBST (TBS containing 0.2% Triton X-100 (Sigma, Cat. No. T 9284) 5 mg/ml BSA (Roche, Cat.

25 No. 100377), and 0.05% NaN₃), 1:1000 DM1A monoclonal antibody (mouse IgG1, Sigma, Cat. No. T 9026), 1:1000 Alexa-Fluor® 488 (Molecular Probes, Cat. No. A-11029 goat anti-mouse at 488 nm), and 10 microliters of a 1 mg/mL stock of DAPI

stain (Sigma, Cat. No. D 9542). The plates were then stored at 4°C for 1-2 hours prior to being rinsed with TBST and imaged.

Procedure for Tabulation of Imaging Data from the KIF14 siRNA Time Course:

HeLa cells were counted manually from individual 40x fields obtained from the 96-well plates stained according to the procedure for immunofluorescence. Each cell was categorized as being in: (1) cytokinesis, (2) other phases of a mitosis of normal appearance, (3) other phases of mitoses of abnormal appearance (tripartite metaphases, asters or partial asters, lagging chromosomes, etc.), (4) interphase with two nuclei (binucleate), (5) interphase with greater than two nuclei (multinucleate), (6) apoptosis (characterized by blebbing and/or rounding and condensed chromatin), or (7) other. No cell was counted more than once for the above analysis. The total number of cells per field was also assessed, counting binucleate, multinucleate, or cells still in the process of cytokinesis as single cells.

Results: Table 5 shows the percentage of total cells in cytokinesis, the percentage of cells in normal mitoses, the percentage of cells in abnormal mitoses, the percentage of binucleate cells, the percentage of multinucleate cells, and the percentage of apoptotic cells. These results suggest that the KIF14 may be involved in cytokinesis, and that reduction of KIF14 expression using RNA interference may result in aberrant cytokinesis, the formation of binucleate cells, and apoptosis.

Table 5. Data from KIF14 siRNA Time Course

	Control	KIF14-4476 (SEQ ID NO:8)			KIF14-5128 (SEQ ID NO:9)		
	Average of 3 time points	24 h	48 h	72 h	24 h	48 h	72 h
Cytokinesis (%)	4	14	8	7	20	14	6
Normal Mitosis (%)	3	1	2	0.9	3	1	2
Abnormal Mitosis (%)	3	0.3	0.6	0.9	0.7	0.7	0.5
Binucleate Cells (%)	5	6	7	9	4	10	9
Multinucleate Cells (%)	1	0.3	2	2	1	3	3
Apoptotic Cells (%)	0.3	1	4	13	2	6	13

	Control	KIF14-4476 (SEQ ID NO:8)			KIF14-5128 (SEQ ID NO:9)		
	Average of 3 time points	24 h	48 h	72 h	24 h	48 h	72 h
Total Cells Counted	377	294	531	444	307	430	373

EXAMPLE 6

This Example describes that transfection of KIF14 siRNAs of different potencies results in more pronounced cytokinesis phenotypes in tumor cells than in normal cells.

5 Transgene overexpression, antibody microinjection and siRNA mediated gene silencing have been used to define the requisite roles of Rab6-KIFL, CHO1, and MPHOSPH1, three mammalian N6 kinesins that regulate cytokinesis (Hill et al. (2000) *EMBO J.* 19(21):5711-9; Matulienė et al. (2002) *Mol. Biol. Cell.* 13(6):1832-45; Abaza et al. (2003) *J. Biol. Chem.* 278(3):27844-52). Phenotypes associated with the functional
10 disruption of these gene products include induction of apoptosis, and/or formation of binucleate and multinucleate cells, all of which result from defects in cytokinesis (Hill et al. (2000) *EMBO J.* 19(21):5711-9; Matulienė et al. (2002) *Mol. Biol. Cell.* 13(6):1832-45; Abaza et al. (2003) *J. Biol. Chem.* 278(3):27844-52). In this example, multiple siRNAs targeting KIF14 were used to investigate the effects of KIF14 depletion on cell
15 division.

Cell culture and siRNA transfection: HCT116 and HeLa-S3 cells were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco). Human renal epithelial cells (HRE) were obtained from Cambrex (East Rutherford NJ). HRE cells were cultured in bullet kit (CC-3190) supplemented REGMTM according to Cambrex recommendations.
20 All three cell lines were cultured at 37°C in 5% CO₂. For siRNA transfections cells were seeded in 6-well (9.60 cm²) culture dishes at a density of 60,000-90,000 cells/well in 2 ml of an appropriate growth medium containing serum and incubated under normal growth conditions. Twenty-four hours after seeding, 100 pmols of siRNA was diluted in 70 microliters of serumfree OPTIMEM[®] and for complex formation, 5 microliters of
25 Oligofectamine[®] (Invitrogen) transfection reagent diluted in 20 microliters of serumfree OPTIMEM was added to the diluted siRNA. After 20 minutes of incubation at room temperature, siRNA:Oligofectamine complexes were added drop-wise to cells directly.

Cells were then incubated with the transfection complexes under their normal growth conditions until their collection for analysis at specific timepoints post transfection. All siRNA duplexes were purchased from Dharmacon (Lafayette CO.) Two KIF14 siRNA sequences and one KSP siRNA sequence were used. KIF14:204
 5 (5' AAACUGGGAGGCUACUUAUACTT 3', SEQ ID NO:8), designated as weak, was selected using Tuschl rules (AA leading dimer, ≥ 75 bases downstream of the ATG, GC% range) and a specificity screen for FASTA hits. KIF14:3053
 (5' GUUGGCUAGAAUUGGGAAATT 3', SEQ ID NO:23), designated as strong, was selected by a pseudorandom design algorithm which selects siRNAs evenly distributed
 10 across the gene in terms of GC%, base pair start and leading dimers. KSP:119
 (5' GGACAACUGCAGCUACUCUTT 3', SEQ ID NO:24) was selected using oligoengineTM siRNA design software. Luciferase siRNA
 (5' CGUACGCGGAUACUUCGAdTdT 3', SEQ ID NO:10) was used as a control.

Quantitative PCR: Transfected cells were lysed in RLT buffer (Qiagen RNeasy
 15 Kit) containing 1% BME. Lysates were homogenized using QIAshredder spin columns (Qiagen) and total cellular RNA was purified using the RNeasy Mini kit (Qiagen). cDNA was synthesized from RNA using random primers and the reverse transcription reagent kit (Applied Biosystems). KIF14 and Glucuronidase beta (hGUS) mRNA expression was measured using Taqman real-time RT-PCR (SDS 7000 system, Applied
 20 Biosystems). Gene specific primer probes for KIF14 (Hs00208408) and hGUS (4310888E) were obtained from Applied Biosystems. Relative KIF14 expression was determined using the following calculation: relative expression = $2^{-\Delta\Delta C_t}$ where the $\Delta\Delta C_t$
 $= (C_{t_{\text{target}}} - C_{t_{\text{hGUS}}})_{\text{KIF14 siRNA}} - (C_{t_{\text{target}}} - C_{t_{\text{hGUS}}})_{\text{Luciferase siRNA}}$.

Western blot analysis of KIF14 expression: Transfected cells were trypsinized,
 25 collected by centrifugation (5 minutes at 300 x g), and washed once with PBS. Cell pellets were resuspended in a small volume (<100 microliters) lysis buffer (20 mM Tris HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1X protease inhibitor mix (Roche Complete®)) and incubated 10 minutes on ice. Following centrifugation (10 minutes at 10000 x g), supernatant was collected and protein concentration
 30 determined using Bio-Rad DC Protein assay kit. 25 micrograms of each sample was subjected to SDS-PAGE on Bio-Rad Ready-Gels (7.5% acrylamide or 4-15% acrylamide gradient). Proteins were transferred to a nitrocellulose membrane using a Bio-Rad Mini Trans-Blot® Transfer Cell according to manufacturer's instructions. Membrane was

blocked in TBS-T buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.6, 0.1% Tween-20) containing 5% non-fat dry milk (blocking buffer) for 30 minutes at room temperature with agitation. Membrane was then incubated with affinity-purified rabbit polyclonal anti-KIF14 (Abcam Inc. ab3746) diluted 1:1000 in blocking buffer for 90 minutes at room temperature with agitation. Membrane was washed 3 times in TBS-T then re-blocked. Membrane was incubated with HRP-conjugated goat anti-rabbit IgG (Zymed) diluted 1:10000 in blocking buffer for 45 minutes at room temperature with agitation. Following three washes in TBS-T, membrane was incubated in chemiluminescence detection reagents (ECL-plus, Amersham) and the image was captured using a CCD camera (Kodak Image Station 440CF).

Cell Cycle Analysis: To analyze cell cycle profiles, approximately 1×10^5 to 5×10^5 cells were harvested along with their accompanying media and pelleted by centrifugation in order to obtain both adherent and detached cells for subsequent flow cytometric analysis. Cells were resuspended in 200 microliters of PBS and fixed by addition of 1 ml of 100% cold ethanol on ice for 30 minutes. Cells were then pelleted and washed once with PBS to break up any clumps. Ethanol fixed cells were incubated at 37°C for 30 minutes in PBS containing 10 micrograms/ml propidium iodide and 1 mg/ml RNaseA. For each sample, 10,000 events were collected using a FACSCalibur™ flow cytometer (Becton Dickinson) and incorporation of propidium iodide was used as a marker for DNA content. Cell cycle profiles were analyzed using FlowJo cytometry analysis software version 4.0.2.

BrdU incorporation Assay: HeLa-S3 and HRE were seeded separately in 96 well plates, (3×10^3 cells/well), in 100 microliters of growth media. Twenty-four hours after seeding, cells were transfected with various siRNA oligos. Transfections were performed in accordance with the 6 well protocol described above. The amount of siRNA:oligofectamine complex added to 200 microliters media was adjusted to maintain a final siRNA concentration of 50 nM/well. Cellular proliferation was measured at 24, 48 and 72 hr post transfection using the colorimetric BrdU ELISA (Roche Applied Science). Cells were pulsed with 10 nM BrdU for 2.5 hr at 37°C prior to cell fixation and DNA denaturation in accordance with the manufacturer's protocol (Roche). Fixed cells were incubated with 100 microliters of peroxidase-conjugated monoclonal anti-BrdU-POD antibody, diluted 1:100 (Roche), for 90 minutes at room temperature. Cells were then washed 3 times with 250 microliters 1X PBS and incubated with 100 microliters substrate

solution (Roche) at room temperature until the appearance of a visible color difference was detectable between positive and negative controls. Light emission of each sample was measured at 370 nm (reference wavelength at 492 nm) using a spectrophotometer.

Results: Depletion of KIF14 induces tumor selective phenotypes that are associated with defects in cytokinesis and are a function of siRNA potency, as shown in Table 6. HeLa and HRE cells were transfected with four separate siRNA duplexes at 100 nM each (luciferase, KIF14:20, KIF14:3053, and KSP:119). Samples transfected with KIF14-specific siRNAs were analyzed 72 hours post transfection, and samples transfected with KSP-specific siRNA were analyzed 48 hours post transfection.

Table 6. Cell Cycle Profiles for siRNA-Transfected Cells

Cells	siRNA	SubG1 (%)	Tetraploid (%)	Polyploid (%)
Hela	Luciferase	3.19	15	3.2
	KIF14:204	49.5	11.5	1.67
	KIF14:3053	3.88	26.7	29
	KSP:119	43.5	30	5
HRE	Luciferase	3.26	13.4	1.08
	KIF14:204	11.4	12.9	1.25
	KIF14:3053	11.2	25.3	3.52
	KSP:119	2.14	57.3	1.52

Two specific phenotypes were observed in response to KIF14 silencing depending on the potency and endpoint efficacy of the particular siRNA. Weak siRNAs, such as KIF14:204, produced about 60 to about 80% KIF14 silencing and elicited apoptosis that was maximal at three days post transfection (Table 6) accompanied by an increase in binucleate cells. This phenotype is consistent with failure to complete cytokinesis after midbody formation (Abaza et al. (2003) *J. Biol. Chem.* 278(3):27844-52). Strong siRNAs, such as KIF:3053, produced more than about 80% KIF14 silencing and induced a marked accumulation of cells exhibiting tetraploid (4N) and polyploid (>4N) DNA content (Table 6) and multinucleate cells. Although evidence of cell death following transfection with strong KIF14 siRNAs was not seen in the shorter term experiment

shown in Table 6, other experiments showed that such cells had a significant decrease in colony forming capacity. Continued chromosomal replication in the absence of cell division (endoreduplication) may occur in cells, such as HeLa, lacking a functional TP53- and RB1-regulated tetraploid checkpoint, which blocks the proliferation of cells that have entered G1 with a 4N DNA content (Hill et al. (2000) *EMBO J.* 19(21):5711-9). These polyploid cells would not be expected to persist in long term growth and would not form colonies. Therefore, the phenotypes elicited by both weak and strong KIF14 siRNAs indicate a role for KIF14 in cytokinesis.

Pronounced cytokinesis defects and/or apoptosis were also observed in other tumor cells following KIF14 depletion (SW480, HCT116 and A549). However, siRNA-mediated depletion of KIF14 in normal human renal epithelial cells (HRE) induced much more modest effects: there was an about 20% increase in binucleate cells and an about 50% reduction in overall cell growth after three days. Thus, KIF14 effects on cytokinesis were more pronounced in the tumor cells tested than in the normal cells. This tumor cell selectivity was not due to differences in KIF14 depletion, as silencing of KIF14 mRNA and protein were similar in both cell types. This selectivity was more pronounced for KIF14 depletion than for depletion of KSP (KIF11) (Table 6) or other mitotic kinesins with known roles in cytokinesis (KNSL5, RAB6-KIFL, and MPP1), spindle formation or chromosome movement (MCAK, CENPE).

The reason for tumor cell selectivity in KIF14 depletion is not currently understood. One plausible explanation from the literature is that most tumor cells lack the TP53/RB1-regulated tetraploid checkpoint.

EXAMPLE 7

This Example describes the expression and functional characterization of KIF14 motor domains.

Materials: *Pfu* polymerase and *E. coli* BL21 (DE3) was obtained from Stratagene. T4 DNA ligase, *NdeI* and *XhoI* were obtained from New England Biolabs. Ampicillin, carbenicillin was obtained from Sigma. pET22b was purchased from Novagen. *E. coli* TOP10 were from Invitrogen. MgCl₂, Tris-Cl, NaCl, imidazole, β-mercaptoethanol, lysozyme, PIPES, BSA, EGTA, and Na-ATP were purchased from Sigma. Tween was purchased from Aldrich, DTT was from Promega and KCl was from

Fisher. Taxol® and tubulin (used to make microtubules) was purchased from Cytoskeleton. Quinaldine Red is from Acros.

K14 Motor Domain Cloning: The DNA sequence encoding a KIF14 motor domain (MD) spanning from V342 to K720 (SEQ ID NO:4) was amplified by Pfu polymerase in a PCR from a KIF14 cDNA (SEQ ID NO:1) cloned into a pBluescript plasmid vector. The primers used to amplify the DNA had flanking sequences that installed an *NdeI* site at the 5' end and an *XhoI* site at the 3' end (Primer 1: 5'-GTCTAGACATATGGTTCAGAACACCTCTGCA-3', SEQ ID NO:11; Primer 2: 5'-TGCCTCGAGCTTCAATTCTCTAATTAAGTT-3', SEQ ID NO:12). An internal *NdeI* site was destroyed using a mutagenesis procedure known as Splicing by Overlap Extension (SOE). The resulting fragment was digested with the restriction endonucleases *NdeI* and *XhoI* and ligated to similarly treated pET22b plasmid vector. The ligation mixture was transformed into chemically competent *E. coli* TOP10 cells, cells selected for with ampicillin and desired clones screened for by Restriction Fragment Length Polymorphism (RFLP) and dideoxy nucleotide sequencing. A single positive clone was used as a PCR template with two additional primers (Primer 3: 5'-GTCTAGACATATGGTAGAGAATAGTCAAGTG-3', SEQ ID NO:13; Primer 4: 5'-TGCCTCGAGATCTTCATTTACTTTAGCAAT-3', SEQ ID NO:14) to generate DNA encoding three smaller MDs spanning from V342-D710 (SEQ ID NO:5), V354-K720 (SEQ ID NO:6), and V354-D710 (SEQ ID NO:7). All were digested, ligated and screened as was the original to generate single positive clones in the pET22b plasmid vector. The pET22b vector appends a DNA sequence to the gene that results in the expressed protein bearing 6 histidine residues at its C-terminus.

KIF14 Motor Domain Expression: All four clones were transformed into *E. coli* BL21 (DE3) cells and single colonies selected for gene expression. Cultures (0.5 L) were grown in Luria-Bertani medium supplemented with 2 mM MgCl₂ and 50 micrograms/mL carbenicillin at 18°C for 50 hours after inoculation with a freshly saturated culture to 1% final volume. Cells were harvested by centrifugation and stored at -80°C.

KIF14 Motor Domain Purification: All of the purification procedures were performed at 4°C. Cells were suspended in a lysis buffer (20 mM Tris-Cl pH 8.0, 300 mM NaCl, 0.1% Tween, 10 mM imidazole, 2 mM MgCl₂, and 5 mM β-mercaptoethanol) to which lysozyme was added to 1 mg/mL and allowed to react 10 min at 4°C. Cells were lysed in a Fisher Sonicator using a microtip with 4 pulses of

30 seconds each. Lysate was clarified by centrifugation at 60,000 x g for 30 min and batch bound to Qiagen Nickel-NTA Superflow resin (bed volume 0.25 mL) for 120 min. Resin was collected by low-speed centrifugation and transferred to a Bio-Rad disposable column, where it was washed with 20 column volumes of lysis buffer. Protein was eluted
5 from the resin with a step gradient of 5 column volumes of lysis buffer containing 20, 50, 100, 150 and 250 mM imidazole. Samples (10 microliters) of each fraction was analyzed on a 4-20% Tris-glycine SDS-PAGE gel (Novex). Fractions containing at least 50% of KIF14 MD (MW between 44.0 and 41.6 kDA) were pooled and dialyzed against 400 volumes of 20 mM Tris pH 8.0, 50 mM KCl, 2 mM MgCl₂, 0.1% Tween, 1 mM DTT
10 and concentrated five-fold in a Centricon-30 (Amicon). Protein determination was according to the method of Bradford. Samples were divided into 5-6 aliquots, flash frozen in liquid N₂ and stored at -80°C.

KIF14 Motor Domain Assay: KIF14 MDs were assayed for microtubule (MT)-dependent ATP hydrolysis by measuring the rate of inorganic phosphate (Pi) release
15 using the dye Quinaldine Red, which absorbs light of 540 nm when bound to Pi. Assays (50 microliters) contained 50 mM K-PIPES pH 6.9 (which contains 90 mM KCl), 1 mM EGTA pH 8.0, 1mM DTT, 100 micrograms/mL BSA, 2 mM MgCl₂, 1 mM Na-ATP pH 7.0, 0.25-5 micromolar MT (which contain equimolar amounts of Taxol®), and 20-200 nM KIF14 MD enzyme. Reactions were initiated by the addition of enzyme and
20 allowed to proceed at room temperature until they were quenched at regular time intervals by the addition of 50 microliters of 1.8 M KCl, 50 mM EDTA. To this was added 150 microliters of the Quinaldine Red dye solution (0.07 mg/mL quinaldine red, 0.09% polyvinyl alcohol, 4.1 mM ammonium molybdate, and 380 mM H₂SO₄). After 10 min incubation at room temperature, absorbance at 540 nM was read on a Molecular
25 Devices Microtiter plate reader. Rates were calculated using the linear (steady-state) phase of the reaction.

Results: Table 7 shows the kinetic utilization of taxol-stabilized microtubules by partially purified KIF14 MD protein extracts prepared from *E. coli* cells expressing the four different KIF14 MD clones. k(obs) (min⁻¹) refers to the rate of product formed (in
30 micromoles/min) divided by the amount of enzyme (in micromoles). [Pi] released refers to the amount of product formed (in micromoles), and forms the numerator in the calculation of rate. All of the KIF14 MD proteins showed microtubule-dependent ATP hydrolysis activity. V342-K720 (SEQ ID NO:4) and V354-K720 (SEQ ID NO:6)

displayed superior (and comparable) kinetic efficiency. These data demonstrate that the KIF14 MD protein, having sequence homology to other previously identified kinesins, such as Eg5 (Mayer et al. (1999) *Science* 286:971-974), has microtubule-dependent ATP hydrolysis activity characteristic of other known kinesin proteins.

5

Table 7. Kinetic Utilization of Taxol-Stabilized Microtubules by KIF14 MDs

MT [micromolar]	V342-K720 (SEQ ID NO:4) k(obs) (min-1)	V342-D710 (SEQ ID NO:5) k(obs) (min-1)	V354-K720 (SEQ ID NO:6) k(obs) (min-1)	V354-D710 (SEQ ID NO:7) k(obs) (min-1)
0	0.00	0.00	0.00	0.00
0.25	0.36	0.03	0.73	0.39
0.5	1.57	0.73	1.49	1.07
1	2.79	0.79	4.12	1.87
2.5	9.10	3.02	9.29	5.79
5	13.25	5.91	18.30	10.18

A comparison of the kinetic characteristics of two of the KIF14 MDs with a panel
10 of other human kinesin motor domains is shown in Table 8.

Table 8. Kinetic Characteristics of Human Kinesin Motor Domains

Motor Domain (amino acids)	Catalytic Rate (s ⁻¹)	K _m (ATP) (micromolar)	K _{1/2} (MT) (micromolar)
hu-KSP (1-367H) (SEQ ID NO:15)	8.5	30	0.3
hu_KIF3A (1-350H) (SEQ ID NO:16)	62.2	270	0.17
hu_uKHC (1-337H) (SEQ ID NO:17)	14.9	1200	0.34
hu_nKHC (1-340H) (SEQ ID NO:18)	2.6	900	1.1
hu_CENP-E (1-340H) (SEQ ID NO:19)	6.8	240	1.6
hu_MKLP-1 (1-433H) (SEQ ID NO:20)	1.5	n.d.	0.24
hu_KIF1B (1-350H) (SEQ ID NO:21)	10.2	140	0.035
hu_KIF14 (342-720) (SEQ ID NO:4)	1.1	n.d.	10.6

Motor Domain (amino acids)	Catalytic Rate (s ⁻¹)	K _m (ATP) (micromolar)	K _{1/2} (MT) (micromolar)
hu_KIF14 (354-720) (SEQ ID NO:6)	0.235	n.d.	n.d.

n.d. Not determined.

The kinetic parameters of the utilization of taxol-stabilized microtubules by KIF14 V342-K720 (SEQ ID NO:4) were obtained by fitting the data to the Michaelis-Menten equation, resulting in a k_{cat} of 21.3 +/- 3.5 (s.d.) and a K_m of 2.6 +/- 1.1 (s.d.).

EXAMPLE 8

This Example describes the optimization of the efficiency of microtubule use of KIF14 motor domain v342-K720 (SEQ ID NO:4).

Two-Step Purification of KIF14 Motor Domain: The purification of the KIF14 motor domain v342-K720 (SEQ ID NO:4) up to the dialysis step was as described in EXAMPLE 7. Overnight dialysis was into cation exchange column buffer (50 mM HEPES pH 6.8, 1 mM MgCl₂, 1 mM EGTA, 1 mM DTT). Sample was applied onto an equilibrated 5 mL HiTrap SP HP, washed with 10 column volumes buffer, then eluted with a linear gradient to 750 mM KCl in buffer over 12 column volumes at a flowrate of 2 mL/min. Fractions (2 mL) were analyzed by SDS-PAGE (10%), and fractions with KIF14 MD purity of more than 90% were pooled, concentrated in a Centricon-30, and stored in 10% sucrose at -80°C. This procedure resulted in a yield of 0.4 mg/L of KIF14 V342-K720 motor domain (SEQ ID NO:4) with a purity of more than 95%.

Optimization of pH and Ionic Strength for KIF14 Motor Domain Activity: To optimize pH and ionic strength, the motor domain assay was performed as described in EXAMPLE 7, with the following modifications. For pH optimization, a series of 50 mM MES buffers spanning a pH range of 5.5 to 6.9, each with constant ionic strength, was used. For ionic strength optimization, the buffer was 50 mM MES pH 5.9 (containing 20 mM KCl) to which was added from 20 to 120 mM additional KCl. The pH optimum for the activity of the KIF14 V342-K720 MD protein (SEQ ID NO:4) was determined to be about 5.9. The optimal ionic strength of the buffer for KIF14 V342-K720 MD (SEQ ID NO:4) activity was found to be about 40 mM KCl.

Optimization of the pH and ionic strength resulted in increased efficiency of microtubule use by the KIF14 V342-K720 MD protein (SEQ ID NO:4). For example the k_{cat}/K_m for the V342-K720 motor domain (SEQ ID NO:4) under unoptimized conditions (K-PIPES, pH 6.7, 90mM KCl) was 224, compared to 13.2 under optimized conditions
5 (MES, pH 6.0, 40 mM KCl).

Characterization of KIF14 Motor Domain Binding to Mg^{2+} and ATP: The motor domain assay was as described above, except that 50 mM MES pH 6.0, 20 mM added KCl was used, and either the $MgCl_2$ concentration was varied from 0 to 4 mM or the ATP concentration was varied from 0 to 1 mM. The optimal concentration of $MgCl_2$ for
10 the activity of the KIF14 V342-K720 MD (SEQ ID NO:4) protein was found to be 1 mM. The minimum ATP concentration to achieve the maximal rate was determined to be 250 mM.

Effect of Temperature on KIF14 Motor Domain Activity: The motor domain assay was as described above, using 50 mM MES pH 6.0, 20 mM added KCl and varying the
15 temperature was varied from 21°C to 37°C. The rate of product formation by KIF14 V342-K720 MD (SEQ ID NO:4) was observed to increase 4.1 fold as temperature was increased from 21°C to 37°C.

Suitability of K14 Motor Domains for high-throughput screening: The motor domain assay was as described above, using 50 mM MES pH 6.0, 20 mM added KCl,
20 0.5 micromolar MTs, a temperature of 37°C, and varying enzyme concentration from 0 to 10 nM. The signal to background ratio, calculated as the amount of Pi formed after a 90 minute incubation in the presence of enzyme relative to in the absence of enzyme, was determined using different concentrations of the V342-K720 motor domain (SEQ ID NO:4), and is shown in Table 9. A high enough signal over background was obtained at
25 low enzyme concentrations to allow high-through-put screening (HTS). Moreover, the V342-K720 motor domain (SEQ ID NO:4) was stable in the reaction for at least 90 minutes.

Table 9. Signal to Background Ratio at Different KIF14 Motor Domain concentrations

Enzyme concentration (nM)	Signal to Background Ratio
40	27
20	21
10	141
5.0	78
2.5	39

5

EXAMPLE 9

This Example describes the identification of modulators of the activity of KIF14 motor domains.

Screen for KIF14 Modulators: The ATPase assay described in EXAMPLE 7, as optimized in EXAMPLE 8, was used to screen for compounds that modulated the activity of the KIF14 V342-K720 MD protein (SEQ ID NO:4). Some of the compounds tested were found to be candidate inhibitors of the KIF14 V342-K720 MD protein (SEQ ID NO:4), and four of these had selective inhibitory activities against the KIF14 MD compared to related kinesin motor domains KSP (SEQ ID NO:15), KIF3A (SEQ ID NO:16), uKHC (SEQ ID NO:17), nKHC (SEQ ID NO:18), CENP-E (SEQ ID NO:19), MKLP-1 (SEQ ID NO:20), KIF1B (SEQ ID NO:21), and MCAK (SEQ ID NO:22), as shown in Table 10. These four compounds were 1,1'-biphenyl-4-carbaldehyde thiosemicarbazone (compound 1), 4-isopropylbenzaldehyde thiosemicarbazone (compound 2; see, e.g., U.S. Patent No. 3,849,575); 4-cyclohexylbenzaldehyde thiosemicarbazone (compound 3); and 4-isopropyl-3-nitrobenzaldehyde thiosemicarbazone (compound 4; see, e.g., Saripinar et al. (1996) *Arzneimittel-Forschung* 46(II):824-8).

Table 10. Characterization of 4 KIF14 MD Inhibitors

IUPAC Name	Structure	KIF14 ATPase IC ₅₀ (nM)	KIF3A ATPase IC ₅₀ (nM)	KSP ATPase IC ₅₀ (nM)	uKHC, nKHC, GEPH-E, MKLP-1, KIF1B, MCAK ATPase IC ₅₀ (nM)
1,1'-biphenyl-4-carbaldehyde thiosemicarbazone (compound 1)		182 (n=2)	631 (n=2)	>40000 (n=2)	>40000
4-isopropylbenzaldehyde thiosemicarbazone (compound 2)		895 (n=2)	30962 (n=2)	25052 (n=2)	>40000
4-cyclohexylbenzaldehyde thiosemicarbazone (compound 3)		76 (n=2)	699 (n=3)	1529 (n=2)	>40000
4-isopropyl-3-nitrobenzaldehyde thiosemicarbazone (compound 4)		54 (n=2)	1550 (n=2)	1099 (n=2)	>40000

Characterization of Candidate KIF14 Modulators in HeLa Cells: The effect of the 4 candidate KIF14 inhibitors identified in the screen (compounds 1-4) were tested in HeLa cells using the alamarBlue™ assay for cell growth described in EXAMPLE 4. HeLa cells were plated at a density of 2000/cells per well in 10% DMEM in a 96-well plate (Costar, Cat. No. 3606) 20 hours prior to treatment with a KIF14 inhibitory compound in a series of dilutions (20 microliters of 11-fold concentrated solution of the compound added to 200 microliters of media). The cells were incubated at 37°C for 72 hours prior to replacement of 100 microliters per well of the media with 10% (vol/vol) alamarBlue™ reagent. After incubation for 2 hours at 37°C, the plates were read on a spectrofluorimeter SpectroMax Gemini (excitation 544 nm, emission 590 nm). The background value (averaged from wells with no cells) was subtracted from each reading. The readings were normalized to 0% inhibition (or 100% viability) with the DMSO control and to 100% inhibition (or 0% viability) with a maximum inhibitory concentration of candidate KIF14 modulator. The three candidate KIF14 modulators tested exhibited an IC₅₀ between 1.0 and 5.0 micromolar, as shown in Table 11.

Table 11. Growth Inhibition in HeLa Cells by Candidate KIF14 Modulators

[Compound](nm)	Compound 1	Compound 2	Compound 3
19.5	-3.58	-5.39	8.97
39.1	-4.74	-8.04	5.97
78.1	-2.50	-5.77	8.16
156.2	5.29	-8.75	6.91
312.5	10.32	-7.21	8.88
625	12.76	-5.51	12.32
1250	19.73	-9.63	7.53
2500	51.68	-2.57	44.36
5000	48.18	29.41	83.84
10000	40.98	61.19	95.02
IC ₅₀	1.0 micromolar (submaximal inhibition)	5.0 micromolar (submaximal inhibition)	2.8 micromolar

Characterization of Candidate KIF14 Modulators in A2780 Cells: The effect of the four candidate KIF14 inhibitors identified in the screen (compounds 1-4) were tested in A2780 cells using the alamarBlue™ assay for cell growth described in EXAMPLE 4.

5 A2780 cells were plated at a density of 4000/cells per well in RPMI1640 (containing 10% FBS, 1% Pen/Strep, 0.01 mg/ml insulin) in a 96-well plate (Costar, Cat. No. 3606) 16 hours prior to treatment. A compound dilution plate was prepared from a 10 mM stock solution using a 3-fold serial dilution series in DMSO. A 1.2 microliter aliquot of each concentration was transferred into 0.6 ml of medium. A 100 microliter aliquot of

10 each concentration was added to the appropriate wells already containing 100 microliters of compound-free medium. After a 48 hour incubation at 37°C, 20 microliters of alamarBlue™ was added to each well (10% vol/vol). After an additional 6 hour incubation at 37°C, the plates were read on a spectrofluorimeter SpectroMax Gemini (excitation 544 nm, emission 590 nm). The background value (averaged from wells with

15 no cells) was subtracted from each reading. The readings were normalized to 0% inhibition (or 100% viability) with the DMSO control and to 100% inhibition (or 0% viability) with a known control compound. The 4 candidate KIF14 modulators tested exhibited an EC₅₀ between more than 10000 and 3600 nM, as shown in Table 12.

Table 12. Growth Inhibition in A2780 Cells by Candidate KIF14 Modulators

[Compound] (nM)	Compound 1	Compound 2	Compound 3	Compound 4
0	5.0	5.0	5.1	1.5
13.7	-4.5	-1.0	-5.3	-7.0
14.1	11.6	14.6	-8.1	-4.0
123	-10.3	-18	-10.4	-9.2
370	19.0	9.4	7.8	4.4
1111	18.7	17.1	6.0	7.5
3333	23.6	-2.6	39.8	25.0
10000	31.3	64.8	107.1	61.8
EC ₅₀ (nM)	>10000	8540	3600	7980

- 5 While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method for screening for modulators of a target protein, comprising the steps of contacting a target protein with a candidate agent and determining whether the candidate agent modulates the activity of the target protein, wherein the target protein comprises a sequence that has more than 80% amino acid sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3.

2. The method of Claim 1, wherein (a) the target protein is contacted with the candidate agent at a first concentration and a first level of activity of the target protein is measured; and (b) the target protein is contacted with the candidate agent at a second concentration and a second level of activity of the target protein is measured, wherein a difference between the first level of activity and the second level of activity of the target protein indicates that the candidate agent modulates the activity of the target protein.

3. The method of Claim 1, wherein the target protein is contacted with the candidate agent *in vivo*.

4. The method of Claim 1, wherein the target protein is contacted with the candidate agent *in vitro*.

5. The method of Claim 1, wherein a microtubule-stimulated ATPase assay is used for determining whether the candidate agent modulates the activity of the target protein.

6. The method of Claim 1, wherein a binding assay is used for determining whether the candidate agent modulates the activity of the target protein.

7. The method of Claim 6, wherein a microtubule-binding assay is used for determining whether the candidate agent modulates the activity of the target protein.

8. The method of Claim 1, wherein a microtubule-gliding assay is used for determining whether the candidate agent modulates the activity of the target protein.

9. The method of Claim 1, wherein a high throughput screening assay is used for determining whether the candidate agent modulates the activity of the target protein.

10. The methods of Claim 1, wherein fluorescence, luminescence, radioactivity, or absorbance is used for determining whether the candidate agent modulates the activity of the target protein.

11. The method of Claim 3, wherein contacting the target protein with the candidate agent *in vivo* comprises expressing the target protein in a cell.

12. The method of Claim 3, wherein a cell viability assay is used for determining whether the candidate agent modulates the activity of the target protein.

13. The method of Claim 3, wherein a cell morphology assay is used for determining whether the candidate agent modulates the activity of the target protein.

14. The method of Claim 3, wherein a cell proliferation assay is used for determining whether the candidate agent modulates the activity of the target protein.

15. The method of Claim 3, wherein a cell cycle distribution assay is used for determining whether the candidate agent modulates the activity of the target protein.

16. The method of Claim 3, wherein an apoptosis assay is used for determining whether the candidate agent modulates the activity of the target protein.

17. The method of Claim 1, wherein the target protein comprises the amino acid sequence provided in SEQ ID NO:2, SEQ ID NO:3, or a fragment of SEQ ID NO:3 having ATPase activity.

18. A method of modulating cell proliferation, comprising administering to a cell an effective amount of a modulator of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3.

19. The method of Claim 18, wherein the modulator is administered to a cell *in vivo*.

20. The method of Claim 18, wherein the modulator is an inhibitor.
21. The method of Claim 20, wherein the inhibitor is an RNA inhibitor.
22. The method of Claim 21, wherein the inhibitor is a KIF14 RNA inhibitor.
23. The method of Claim 22, wherein the KIF14 RNA inhibitor comprises the sequence provided in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:23.
24. The method of Claim 20, wherein the inhibitor is a semicarbazone.
25. The method of Claim 20, wherein the inhibitor is a thiosemicarbazone.
26. A method for treating a subject with a cellular hyperproliferation disorder, comprising administering to a subject with a cellular hyperproliferation disorder a therapeutically effective amount of an inhibitor of the activity of a target protein, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3.
27. The method of Claim 26, where the cellular hyperproliferation disorder is cancer.
28. The method of Claim 27, wherein the cancer is breast cancer.
29. The method of Claim 26, wherein the modulator is an inhibitor.
30. The method of Claim 29, wherein the inhibitor is an RNA inhibitor.
31. The method of Claim 30, wherein the inhibitor is a KIF14 RNA inhibitor.
32. The method of Claim 31, wherein the KIF14 RNA inhibitor comprises the sequence provided in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:23.
33. The method of Claim 29, wherein the inhibitor is a semicarbazone.
34. The method of Claim 29, wherein the inhibitor is a thiosemicarbazone.
35. A method for identifying candidate subjects for treatment with an inhibitor of the activity of a target protein, comprising the steps of:

(a) measuring the level of expression of a target protein in abnormally proliferating cells of a subject, wherein the target protein comprises a sequence that has more than 80% sequence identity to the sequence provided in SEQ ID NO:2 or SEQ ID NO:3; and

(b) identifying the subject as a candidate subject for treatment with an inhibitor of the activity of the target protein if the level of expression of the target protein in the abnormally proliferating cells is significantly higher than in control cells.

36. The method of Claim 35, wherein the abnormally proliferating cells are breast cancer cells.

37. The method of Claim 35, wherein the target protein comprises the amino acid sequence provided in SEQ ID NO:2, SEQ ID NO:3, or a fragment of SEQ ID NO:3 having ATPase activity.

38. The method of Claim 35, wherein the level of expression of the target protein in abnormally proliferating cells is determined by measuring at the level of mRNA.

39. The method of Claim 35 further comprising the step of treating the candidate subject with an inhibitor of the activity of the target protein.

1/1




Fig.1.

<110> Rosetta Inpharmatics LLC
Mao, Mao
Linsley, Peter S.
Buser, Carolyn A.
Marshall, Christopher G.
Kim, Annette S.

<120> Methods for Identifying Modulators of Kinesin Activity

<130> ROSA122792

<150> US 60/474,488

<151> 2003-05-30

<150> US 60/475,873

<151> 2003-06-03

<150> US 60/553,838

<151> 2004-03-17

<160> 24

<170> PatentIn version 3.2

 $\langle 210 \rangle$ 1

<211> 6586

<212> DNA

<213> Homo Sapiens

 $\langle 220 \rangle$

<221> CDS

<222> (440) .. (5386)

<400> 1

ctggggagcc ggcgctggag gtggtgagtg gcgtggggac tgtgtcgagg gggcccccaa 60

ggtagccggac cctgcggagg ggcgaagttt cggcactggg gagggcgtgc ggacgctttc 120

cctacaggcg accactgctc tgcgggcggg tggtcttagc tccagtcccc cattcagttc 180

ctcagcattc caggtcggcg gcgaaggggt ccccgaaacga agggcgcaag gcagcgtctc 240

tgctgggacc gggaagccgg acttcagggc ctctcggccc gtgggcttct ccccgagtct 300

ccccgagtcg gttggcatta agagtttagc agatactttc agaaatggat acataaqaaa 360

tggttggaat tcaaataaat gtccaaagaa gagcttaggg tcttagtaac attctttttt 420

aaaataactg tctgccaaa atg tca tta cac agt act cat aat aga aat aac 472

Met Ser Leu His Ser Thr His Asn Arg Asn Asn
1 5 10

agc ggt gat att ctt gat att cct tct tcc caa aat agt tca tca ctg 520

Ser Gly Asp Ile Leu Asp Ile Pro Ser Ser Gln Asn Ser Ser Ser Leu
15 20 25

aat gcc ctc acc cac agt agc cga ctt aag ctg cat ttg aag tcg gat 568

Asn Ala Leu Thr His Ser Ser Arg Leu Lys Leu His Leu Lys Ser Asp

30	35	40	
atg tca gaa tgt gaa aat gat gat cca tta ttg aga tct gca ggt aaa Met Ser Glu Cys Glu Asn Asp Asp Pro Leu Leu Arg Ser Ala Gly Lys 45 50 55			616
gtc aga gac ata aat aga act tat gtt att tct gcc agt aga aaa aca Val Arg Asp Ile Asn Arg Thr Tyr Val Ile Ser Ala Ser Arg Lys Thr 60 65 70 75			664
gca gac atg ccc ctt acc cct aat cct gta ggt aga ttg gca ctt cag Ala Asp Met Pro Leu Thr Pro Asn Pro Val Gly Arg Leu Ala Leu Gln 80 85 90			712
agg aga act aca agg aac aaa gaa tca tct ttg ctt gtt agt gag ttg Arg Arg Thr Thr Arg Asn Lys Glu Ser Ser Leu Leu Val Ser Glu Leu 95 100 105			760
gaa gac aca act gaa aaa aca gca gaa aca cgt ctt aca tta caa cgt Glu Asp Thr Thr Glu Lys Thr Ala Glu Thr Arg Leu Thr Leu Gln Arg 110 115 120			808
cgt gct aaa aca gat tct gca gaa aag tgg aaa aca gct gaa ata gat Arg Ala Lys Thr Asp Ser Ala Glu Lys Trp Lys Thr Ala Glu Ile Asp 125 130 135			856
tct gtc aaa atg aca ctg aat gtg gga ggt gaa aca gaa aat aat ggt Ser Val Lys Met Thr Leu Asn Val Gly Gly Glu Thr Glu Asn Asn Gly 140 145 150 155			904
gtt tct aag gaa agt aga aca aat gta agg att gta aat aat gct aaa Val Ser Lys Glu Ser Arg Thr Asn Val Arg Ile Val Asn Asn Ala Lys 160 165 170			952
aac tct ttt gtt gcc tct tct gta cct tta gat gaa gat cca cag gtc Asn Ser Phe Val Ala Ser Ser Val Pro Leu Asp Glu Asp Pro Gln Val 175 180 185			1000
att gaa atg atg gct gat aag aaa tac aaa gaa aca ttt tct gcc ccc Ile Glu Met Met Ala Asp Lys Lys Tyr Lys Glu Thr Phe Ser Ala Pro 190 195 200			1048
agt aga gca aat gaa aat gtt gca ctt aag tac tca agt aat aga cca Ser Arg Ala Asn Glu Asn Val Ala Leu Lys Tyr Ser Ser Asn Arg Pro 205 210 215			1096
ccc att gct tcc ctg agt cag act gaa gtt gtt aga tca gga cac ttg Pro Ile Ala Ser Leu Ser Gln Thr Glu Val Val Arg Ser Gly His Leu 220 225 230 235			1144
aca acg aaa cct act cag agc aag ttg gat atc aaa gtg ttg gga aca Thr Thr Lys Pro Thr Gln Ser Lys Leu Asp Ile Lys Val Leu Gly Thr 240 245 250			1192
gga aac ttg tat cat aga agt att ggg aag gaa att gca aaa act tca Gly Asn Leu Tyr His Arg Ser Ile Gly Lys Glu Ile Ala Lys Thr Ser 255 260 265			1240
aat aaa ttt ggg agc tta gaa aaa aga aca cct aca aaa tgt aca aca Asn Lys Phe Gly Ser Leu Glu Lys Arg Thr Pro Thr Lys Cys Thr Thr 270 275 280			1288

gaa cac aaa ctg aca aca aag tgc agc ctg cct cag ctt aag agc cca	1336
Glu His Lys Leu Thr Thr Lys Cys Ser Leu Pro Gln Leu Lys Ser Pro	
285 290 295	
gct cca tca ata ctg aag aat aga atg tct aac ctt caa gtt aaa caa	1384
Ala Pro Ser Ile Leu Lys Asn Arg Met Ser Asn Leu Gln Val Lys Gln	
300 305 310 315	
aga cca aaa agt tcc ttt ctt gca aat aaa cag gaa aga tcc gca gaa	1432
Arg Pro Lys Ser Ser Phe Leu Ala Asn Lys Gln Glu Arg Ser Ala Glu	
320 325 330	
aat aca att ctt ccc gaa gaa gaa act gta gtt cag aac acc tct gca	1480
Asn Thr Ile Leu Pro Glu Glu Glu Thr Val Val Gln Asn Thr Ser Ala	
335 340 345	
gga aaa gac ccc tta aaa gta gag aat agt caa gtg aca gtg gca gta	1528
Gly Lys Asp Pro Leu Lys Val Glu Asn Ser Gln Val Thr Val Ala Val	
350 355 360	
cgc gta aga cct ttc acc aag aga gag aag att gaa aaa gca tcc cag	1576
Arg Val Arg Pro Phe Thr Lys Arg Glu Lys Ile Glu Lys Ala Ser Gln	
365 370 375	
gta gtc ttc atg agt ggg aaa gaa ata act gtg gaa cac cct gac acg	1624
Val Val Phe Met Ser Gly Lys Glu Ile Thr Val Glu His Pro Asp Thr	
380 385 390 395	
aaa caa gtt tat aat ttt att tat gat gtt tca ttc tgg tct ttt gat	1672
Lys Gln Val Tyr Asn Phe Ile Tyr Asp Val Ser Phe Trp Ser Phe Asp	
400 405 410	
gaa tgt cat cct cac tac gct agc cag aca act gtc tat gag aag cta	1720
Glu Cys His Pro His Tyr Ala Ser Gln Thr Thr Val Tyr Glu Lys Leu	
415 420 425	
gca gca cca ctc cta gaa aga gcc ttc gaa ggc ttc aat acc tgt ctt	1768
Ala Ala Pro Leu Leu Glu Arg Ala Phe Glu Gly Phe Asn Thr Cys Leu	
430 435 440	
ttt gct tat ggt cag act ggc tct gga aaa tca tat acg atg atg gga	1816
Phe Ala Tyr Gly Gln Thr Gly Ser Gly Lys Ser Tyr Thr Met Met Gly	
445 450 455	
ttt agt gaa gaa cca gga ata att cca aga ttt tgt gaa gat ctt ttt	1864
Phe Ser Glu Glu Pro Gly Ile Ile Pro Arg Phe Cys Glu Asp Leu Phe	
460 465 470 475	
tct caa gta gcc aga aaa caa acc caa gag gtc agc tat cac att gaa	1912
Ser Gln Val Ala Arg Lys Gln Thr Gln Glu Val Ser Tyr His Ile Glu	
480 485 490	
atg agc ttc ttt gaa gta tat aat gaa aaa att cac gac ctt ctg gtt	1960
Met Ser Phe Phe Glu Val Tyr Asn Glu Lys Ile His Asp Leu Leu Val	
495 500 505	
tgt aaa gat gaa aat ggg cag aga aag caa cca ctg aga gtg agg gaa	2008
Cys Lys Asp Glu Asn Gly Gln Arg Lys Gln Pro Leu Arg Val Arg Glu	
510 515 520	

cat	cct	gtt	tat	gga	cca	tat	gtt	gaa	gca	ctg	tca	atg	aac	att	gtc	2056
His	Pro	Val	Tyr	Gly	Pro	Tyr	Val	Glu	Ala	Leu	Ser	Met	Asn	Ile	Val	
	525					530					535					
agt	tct	tac	gct	gat	atc	cag	agt	tgg	cta	gaa	ttg	gga	aat	aaa	caa	2104
Ser	Ser	Tyr	Ala	Asp	Ile	Gln	Ser	Trp	Leu	Glu	Leu	Gly	Asn	Lys	Gln	
540					545					550					555	
aga	gct	act	gct	gct	act	ggt	atg	aat	gat	aaa	agt	tcc	cga	tct	cat	2152
Arg	Ala	Thr	Ala	Ala	Thr	Gly	Met	Asn	Asp	Lys	Ser	Ser	Arg	Ser	His	
					560					565					570	
tca	gtt	ttc	acc	ctg	gtg	atg	acc	cag	acc	aag	aca	gaa	ttt	gtg	gaa	2200
Ser	Val	Phe	Thr	Leu	Val	Met	Thr	Gln	Thr	Lys	Thr	Glu	Phe	Val	Glu	
			575					580					585			
ggg	gaa	gaa	cac	gat	cac	aga	ata	aca	agt	cga	att	aac	cta	ata	gat	2248
Gly	Glu	Glu	His	Asp	His	Arg	Ile	Thr	Ser	Arg	Ile	Asn	Leu	Ile	Asp	
			590				595					600				
ctg	gca	ggc	agt	gag	cgc	tgc	tct	acg	gct	cac	act	aat	gga	gat	cga	2296
Leu	Ala	Gly	Ser	Glu	Arg	Cys	Ser	Thr	Ala	His	Thr	Asn	Gly	Asp	Arg	
	605					610					615					
cta	aag	gaa	ggt	gtg	agt	att	aat	aag	tcc	ttg	cta	act	ttg	gga	aaa	2344
Leu	Lys	Glu	Gly	Val	Ser	Ile	Asn	Lys	Ser	Leu	Leu	Thr	Leu	Gly	Lys	
620					625					630					635	
gtt	ata	tct	gca	ctt	tcg	gaa	caa	gca	aac	caa	agg	agt	gtt	ttt	att	2392
Val	Ile	Ser	Ala	Leu	Ser	Glu	Gln	Ala	Asn	Gln	Arg	Ser	Val	Phe	Ile	
				640						645				650		
cct	tat	cgt	gaa	tct	gtt	ctt	aca	tgg	ctg	tta	aaa	gaa	agt	ctg	ggt	2440
Pro	Tyr	Arg	Glu	Ser	Val	Leu	Thr	Trp	Leu	Leu	Lys	Glu	Ser	Leu	Gly	
			655					660					665			
gga	aat	tca	aaa	act	gca	atg	att	gct	acg	att	agt	ccc	gct	gcc	agc	2488
Gly	Asn	Ser	Lys	Thr	Ala	Met	Ile	Ala	Thr	Ile	Ser	Pro	Ala	Ala	Ser	
			670				675					680				
aac	ata	gaa	gaa	aca	tta	agc	aca	ctt	aga	tat	gct	aac	caa	gcc	cgt	2536
Asn	Ile	Glu	Glu	Thr	Leu	Ser	Thr	Leu	Arg	Tyr	Ala	Asn	Gln	Ala	Arg	
	685					690					695					
tta	ata	gtc	aac	att	gct	aaa	gta	aat	gaa	gat	atg	aac	gct	aag	tta	2584
Leu	Ile	Val	Asn	Ile	Ala	Lys	Val	Asn	Glu	Asp	Met	Asn	Ala	Lys	Leu	
700					705					710					715	
att	aga	gaa	ttg	aag	gca	gaa	att	gca	aag	cta	aaa	gct	gct	cag	aga	2632
Ile	Arg	Glu	Leu	Lys	Ala	Glu	Ile	Ala	Lys	Leu	Lys	Ala	Ala	Gln	Arg	
				720					725					730		
aac	agt	cgg	aat	att	gac	cct	gaa	cga	tac	agg	ctc	tgt	cgg	caa	gaa	2680
Asn	Ser	Arg	Asn	Ile	Asp	Pro	Glu	Arg	Tyr	Arg	Leu	Cys	Arg	Gln	Glu	
			735					740					745			
ata	aca	tcc	tta	aga	atg	aaa	ctg	cat	caa	cag	gag	aga	gac	atg	gca	2728
Ile	Thr	Ser	Leu	Arg	Met	Lys	Leu	His	Gln	Gln	Glu	Arg	Asp	Met	Ala	
		750					755					760				
gaa	atg	caa	aga	gtg	tgg	aaa	gaa	aag	ttt	gaa	caa	gct	gaa	aaa	aga	2776

Glu Met Gln Arg Val Trp Lys Glu Lys Phe Glu Gln Ala Glu Lys Arg	
765	770 775
aaa ctt caa gaa aca aaa gag tta cag aaa gca gga att atg ttt caa	2824
Lys Leu Gln Glu Thr Lys Glu Leu Gln Lys Ala Gly Ile Met Phe Gln	
780	785 790 795
atg gac aat cat tta cca aac ctt gtt aat ctg aat gaa gat cca caa	2872
Met Asp Asn His Leu Pro Asn Leu Val Asn Leu Asn Glu Asp Pro Gln	
	800 805 810
cta tct gag atg ctg cta tat atg ata aaa gaa gga aca act aca gtt	2920
Leu Ser Glu Met Leu Leu Tyr Met Ile Lys Glu Gly Thr Thr Thr Val	
	815 820 825
gga aag tat aaa cca aac tca agc cat gat att cag tta tct ggg gtg	2968
Gly Lys Tyr Lys Pro Asn Ser Ser His Asp Ile Gln Leu Ser Gly Val	
	830 835 840
ctg att gct gat gat cat tgt act atc aaa aat ttt ggt ggg aca gtg	3016
Leu Ile Ala Asp Asp His Cys Thr Ile Lys Asn Phe Gly Gly Thr Val	
	845 850 855
agt att atc cca gtt ggg gaa gca aag aca tat gta aat gga aaa cat	3064
Ser Ile Ile Pro Val Gly Glu Ala Lys Thr Tyr Val Asn Gly Lys His	
	860 865 870 875
att ttg gaa atc aca gta tta cgt cat ggt gat cga gtg att ctt ggt	3112
Ile Leu Glu Ile Thr Val Leu Arg His Gly Asp Arg Val Ile Leu Gly	
	880 885 890
gga gat cat tat ttt aga ttt aat cat cca gta gaa gtc cag aaa gga	3160
Gly Asp His Tyr Phe Arg Phe Asn His Pro Val Glu Val Gln Lys Gly	
	895 900 905
aaa agg cca tct gga aga gat act cct ata agt gag ggt cca aaa gac	3208
Lys Arg Pro Ser Gly Arg Asp Thr Pro Ile Ser Glu Gly Pro Lys Asp	
	910 915 920
ttt gaa ttt gca aaa aat gag ttg ctc atg gca cag aga tca caa ctt	3256
Phe Glu Phe Ala Lys Asn Glu Leu Leu Met Ala Gln Arg Ser Gln Leu	
	925 930 935
gaa gca gaa ata aaa gag gct cag ttg aag gca aag gaa gaa atg atg	3304
Glu Ala Glu Ile Lys Glu Ala Gln Leu Lys Ala Lys Glu Glu Met Met	
	940 945 950 955
caa gga atc cag att gca aaa gaa atg gct cag caa gag ctt tct tct	3352
Gln Gly Ile Gln Ile Ala Lys Glu Met Ala Gln Gln Glu Leu Ser Ser	
	960 965 970
caa aaa gct gca tat gaa agc aaa ata aaa gca ctg gaa gca gaa ctg	3400
Gln Lys Ala Ala Tyr Glu Ser Lys Ile Lys Ala Leu Glu Ala Glu Leu	
	975 980 985
aga gaa gag tct caa agg aaa aaa atg cag gaa ata aat aac cag aag	3448
Arg Glu Glu Ser Gln Arg Lys Lys Met Gln Glu Ile Asn Asn Gln Lys	
	990 995 1000
gct aat cac aaa att gag gaa tta gaa aag gca aag cag cat ctt	3493
Ala Asn His Lys Ile Glu Glu Leu Glu Lys Ala Lys Gln His Leu	

1005	1010	1015	
gaa cag gaa ata tat gtc aac Glu Gln Glu Ile Tyr Val Asn	aaa aag cga tta gaa Lys Lys Arg Leu Met Glu Thr	3538	
1020	1025	1030	
ttg gct aca aaa cag gct tta Leu Ala Thr Lys Gln Ala Leu	gaa gac cat agc atc cgc cat gca Glu Asp His Ser Ile Arg His Ala	3583	
1035	1040	1045	
aga att ctg gaa gct tta gaa Arg Ile Leu Glu Ala Leu Glu	act gaa aag caa aaa att gct aaa Thr Glu Lys Gln Lys Ile Ala Lys	3628	
1050	1055	1060	
gaa gta caa att cta cag cag Glu Val Gln Ile Leu Gln Gln	aat cgg aat aat agg gat aaa act Asn Arg Asn Asn Arg Asp Lys Thr	3673	
1065	1070	1075	
ttt aca gtg cag aca act tgg Phe Thr Val Gln Thr Thr Trp	agc tct atg aaa ctc tca atg atg Ser Ser Met Lys Leu Ser Met Met	3718	
1080	1085	1090	
att cag gaa gcc aat gct atc Ile Gln Glu Ala Asn Ala Ile	agc agc aaa ttg aaa aca tac tat Ser Ser Lys Leu Lys Thr Tyr Tyr	3763	
1095	1100	1105	
gtt ttt ggc aga cat gat ata Val Phe Gly Arg His Asp Ile	tca gat aaa agt agt tct gac act Ser Asp Lys Ser Ser Ser Asp Thr	3808	
1110	1115	1120	
tct att cgg gtt cgt aac ctg Ser Ile Arg Val Arg Asn Leu	aaa cta gga atc tca aca ttc tgg Lys Leu Gly Ile Ser Thr Phe Trp	3853	
1125	1130	1135	
agt ctg gaa aag ttt gaa tct Ser Leu Glu Lys Phe Glu Ser	aaa ctt gca gca atg aaa gaa ctt Lys Leu Ala Ala Met Lys Glu Leu	3898	
1140	1145	1150	
tat gag agt aat ggt agt aac Tyr Glu Ser Asn Gly Ser Asn	agg ggt gaa gat gcc ttt tgt gat Arg Gly Glu Asp Ala Phe Cys Asp	3943	
1155	1160	1165	
cct gaa gat gaa tgg gaa ccc Pro Glu Asp Glu Trp Glu Pro	gac att aca gat gca cca gtt tct Asp Ile Thr Asp Ala Pro Val Ser	3988	
1170	1175	1180	
tca ctt tct aga agg agg agt Ser Leu Ser Arg Arg Arg Ser	agg agt ttg atg aag aac aga aga Arg Ser Leu Met Lys Asn Arg Arg	4033	
1185	1190	1195	
att tct ggt tgt tta cat gac Ile Ser Gly Cys Leu His Asp	ata caa gtc cat cca att aag aat Ile Gln Val His Pro Ile Lys Asn	4078	
1200	1205	1210	
ttg cat tct tca cat tca tca Leu His Ser Ser His Ser Ser	ggt tta atg gac aaa tca agc act Gly Leu Met Asp Lys Ser Ser Thr	4123	
1215	1220	1225	
att tac tca aat tca gca gag Ile Tyr Ser Asn Ser Ala Glu	tcc ttt ctt cct gga att tgc aaa Ser Phe Leu Pro Gly Ile Cys Lys	4168	
1230	1235	1240	

gaa ttg att ggt tct tcg tta gat ttt ttt gga cag agt tat gat	4213
Glu Leu Ile Gly Ser Ser Leu Asp Phe Phe Gly Gln Ser Tyr Asp	
1245 1250 1255	
gaa gaa aga act ata gca gac agc cta att aat agt ttt ctt aaa	4258
Glu Glu Arg Thr Ile Ala Asp Ser Leu Ile Asn Ser Phe Leu Lys	
1260 1265 1270	
att tat aat ggg cta ttt gcc att tcc aag gct cat gaa gaa caa	4303
Ile Tyr Asn Gly Leu Phe Ala Ile Ser Lys Ala His Glu Glu Gln	
1275 1280 1285	
gat gaa gaa agt caa gat aac ttg ttt tct tct gat cga gca atc	4348
Asp Glu Glu Ser Gln Asp Asn Leu Phe Ser Ser Asp Arg Ala Ile	
1290 1295 1300	
cag tca ctt act att cag act gca tgt gct ttt gag cag cta gta	4393
Gln Ser Leu Thr Ile Gln Thr Ala Cys Ala Phe Glu Gln Leu Val	
1305 1310 1315	
gtg cta atg aaa cac tgg ctg agt gat tta ctg cct tgt acc aac	4438
Val Leu Met Lys His Trp Leu Ser Asp Leu Leu Pro Cys Thr Asn	
1320 1325 1330	
ata gca aga ctt gag gat gag ttg aga caa gaa gtt aaa aaa ctg	4483
Ile Ala Arg Leu Glu Asp Glu Leu Arg Gln Glu Val Lys Lys Leu	
1335 1340 1345	
gga ggc tac tta cag tta ttt ttg cag gga tgc tgt ttg gat att	4528
Gly Gly Tyr Leu Gln Leu Phe Leu Gln Gly Cys Cys Leu Asp Ile	
1350 1355 1360	
tca tca atg ata aaa gag gct caa aag aat gca atc caa att gta	4573
Ser Ser Met Ile Lys Glu Ala Gln Lys Asn Ala Ile Gln Ile Val	
1365 1370 1375	
caa caa gct gta aag tat gtg ggg cag tta gca gtt ctg aaa ggg	4618
Gln Gln Ala Val Lys Tyr Val Gly Gln Leu Ala Val Leu Lys Gly	
1380 1385 1390	
agc aag cta cat ttt cta gaa aac ggt aac aat aaa gct gcc agt	4663
Ser Lys Leu His Phe Leu Glu Asn Gly Asn Asn Lys Ala Ala Ser	
1395 1400 1405	
gtc cag gag gaa ttc atg gat gct gtt tgt gat ggt gta ggc tta	4708
Val Gln Glu Glu Phe Met Asp Ala Val Cys Asp Gly Val Gly Leu	
1410 1415 1420	
gga atg aag att tta tta gat tct gga ctg gaa aaa gca aaa gaa	4753
Gly Met Lys Ile Leu Leu Asp Ser Gly Leu Glu Lys Ala Lys Glu	
1425 1430 1435	
ctt cag cat gaa ctc ttt agg cag tgt aca aaa aat gag gtt acc	4798
Leu Gln His Glu Leu Phe Arg Gln Cys Thr Lys Asn Glu Val Thr	
1440 1445 1450	
aaa gaa atg aaa act aat gcc atg gga ttg att aga tct ctt gaa	4843
Lys Glu Met Lys Thr Asn Ala Met Gly Leu Ile Arg Ser Leu Glu	
1455 1460 1465	

aac atc ttt gct gaa tcg aaa att aaa agt ttc aga agg caa gta	4888
Asn Ile Phe Ala Glu Ser Lys Ile Lys Ser Phe Arg Arg Gln Val	
1470 1475 1480	
caa gaa gaa aac ttt gaa tac caa gat ttc aag agg atg gtt aat	4933
Gln Glu Glu Asn Phe Glu Tyr Gln Asp Phe Lys Arg Met Val Asn	
1485 1490 1495	
cgt gct cca gaa ttc tta aag tta aaa cat tgc tta gag aaa gct	4978
Arg Ala Pro Glu Phe Leu Lys Leu Lys His Cys Leu Glu Lys Ala	
1500 1505 1510	
att gaa att att att tct gca ctg aaa gga tgc cat agt gat ata	5023
Ile Glu Ile Ile Ile Ser Ala Leu Lys Gly Cys His Ser Asp Ile	
1515 1520 1525	
aat ctt ctc cag act tgt gtt gaa agt att cgc aac ttg gcc agt	5068
Asn Leu Leu Gln Thr Cys Val Glu Ser Ile Arg Asn Leu Ala Ser	
1530 1535 1540	
gat ttt tac agt gac ttc agt gtg cct tct act tct gtt ggc agc	5113
Asp Phe Tyr Ser Asp Phe Ser Val Pro Ser Thr Ser Val Gly Ser	
1545 1550 1555	
tat gag agt aga gta act cac att gtc cac cag gaa cta gaa tct	5158
Tyr Glu Ser Arg Val Thr His Ile Val His Gln Glu Leu Glu Ser	
1560 1565 1570	
cta gct aag tct ctc ctc ttt tgt ttt gaa tct gaa gaa agc cct	5203
Leu Ala Lys Ser Leu Leu Phe Cys Phe Glu Ser Glu Glu Ser Pro	
1575 1580 1585	
gat ttg ttg aaa ccc tgg gaa act tat aat caa aat acc aaa gaa	5248
Asp Leu Leu Lys Pro Trp Glu Thr Tyr Asn Gln Asn Thr Lys Glu	
1590 1595 1600	
gaa cac caa caa tct aaa tca agc ggg att gac ggc agt aag aat	5293
Glu His Gln Gln Ser Lys Ser Ser Gly Ile Asp Gly Ser Lys Asn	
1605 1610 1615	
aaa ggt gta cca aag cgt gtc tat gag ctc cat ggc tca tcc cca	5338
Lys Gly Val Pro Lys Arg Val Tyr Glu Leu His Gly Ser Ser Pro	
1620 1625 1630	
gca gtg agc tca gag gaa tgc aca ccc agt agg att cag tgg gtg	5383
Ala Val Ser Ser Glu Glu Cys Thr Pro Ser Arg Ile Gln Trp Val	
1635 1640 1645	
tga atactgatgt gtaggcactt ttatgaccac ccatgaaaga aaaagaacac	5436
ttgctcggtta attttcttta tgcaggagag tttaagagaa atcagcacag atatttcaaa	5496
aaagtccatg tctttttatc tttaaaatat ctatttatca aaggccagac acagtggctc	5556
acgcctgtaa tcccagcact ttggggaggcg ggcagatcac aaggtcagga gtttgagacc	5616
ggcctggcca acatggtgaa accccgtctc tactaaaaat acaaaaattt gctgggcatg	5676
gtggcgctg cctgtaatcc cagctactag gggggctgag gcaggaggat cgcttgaacc	5736
tgagaggcag aggttgcagt gagccaagat catgccactt tactccagtc tgagcaacag	5796

```

aacgagactt agtcaaaaata aataaataaa taagtaaata aataaataaa taaaatatct 5856
tttatcttta aagtgtttta cattggtata ctgtctgtag ttgggttcatt agtcgtttat 5916
aaagggttat tttctcatga gtggaaacct gaacaatcag ttacctttgt gcctatgcct 5976
tctctctcct cagacagctg ggatgtttat ggtgaaatgg cctgtacaag tttactaag 6036
acaacttaac ttgcattggt aatcaaaaat tcttttctca aagggttaac tggttgccat 6096
tttgaatagt atgttcaagg gtgtagcttc ctgtttcttt ccaaattata agtagctacc 6156
taaatatagt ataattatat attaataata tggcttgctg gcacagtagt ttacctgtt 6216
atctgtgttt cataatgggg gctgtatgaa tattatttaa aactaataaa atgttgccag 6276
aattatacta aactgttggg tgagattagg agatcagagg ctggaccttc tcttgataat 6336
gcttgttttg ttaaagggtat aatgaaataa tttgtatatg atttgatgaa gattaaagac 6396
ccttattttc cacagcttta aaaaaaaccc tttatttatg atcaagtaat aaagataata 6456
ttctacttgt gggatcttac attatggaaa tagtttgacg tttttgacct caagagtatg 6516
tataatttga agagataactt tgtaactatg cttgggtgat attgagcagt tcctaaagaa 6576
taattcattt 6586

```

```

<210> 2
<211> 1648
<212> PRT
<213> Homo Sapiens

```

```

<400> 2

```

```

Met Ser Leu His Ser Thr His Asn Arg Asn Asn Ser Gly Asp Ile Leu
1          5          10          15

```

```

Asp Ile Pro Ser Ser Gln Asn Ser Ser Ser Leu Asn Ala Leu Thr His
20          25          30

```

```

Ser Ser Arg Leu Lys Leu His Leu Lys Ser Asp Met Ser Glu Cys Glu
35          40          45

```

```

Asn Asp Asp Pro Leu Leu Arg Ser Ala Gly Lys Val Arg Asp Ile Asn
50          55          60

```

```

Arg Thr Tyr Val Ile Ser Ala Ser Arg Lys Thr Ala Asp Met Pro Leu
65          70          75          80

```

```

Thr Pro Asn Pro Val Gly Arg Leu Ala Leu Gln Arg Arg Thr Thr Arg
85          90          95

```

Asn Lys Glu Ser Ser Leu Leu Val Ser Glu Leu Glu Asp Thr Thr Glu
 100 105 110

Lys Thr Ala Glu Thr Arg Leu Thr Leu Gln Arg Arg Ala Lys Thr Asp
 115 120 125

Ser Ala Glu Lys Trp Lys Thr Ala Glu Ile Asp Ser Val Lys Met Thr
 130 135 140

Leu Asn Val Gly Gly Glu Thr Glu Asn Asn Gly Val Ser Lys Glu Ser
 145 150 155 160

Arg Thr Asn Val Arg Ile Val Asn Asn Ala Lys Asn Ser Phe Val Ala
 165 170 175

Ser Ser Val Pro Leu Asp Glu Asp Pro Gln Val Ile Glu Met Met Ala
 180 185 190

Asp Lys Lys Tyr Lys Glu Thr Phe Ser Ala Pro Ser Arg Ala Asn Glu
 195 200 205

Asn Val Ala Leu Lys Tyr Ser Ser Asn Arg Pro Pro Ile Ala Ser Leu
 210 215 220

Ser Gln Thr Glu Val Val Arg Ser Gly His Leu Thr Thr Lys Pro Thr
 225 230 235 240

Gln Ser Lys Leu Asp Ile Lys Val Leu Gly Thr Gly Asn Leu Tyr His
 245 250 255

Arg Ser Ile Gly Lys Glu Ile Ala Lys Thr Ser Asn Lys Phe Gly Ser
 260 265 270

Leu Glu Lys Arg Thr Pro Thr Lys Cys Thr Thr Glu His Lys Leu Thr
 275 280 285

Thr Lys Cys Ser Leu Pro Gln Leu Lys Ser Pro Ala Pro Ser Ile Leu
 290 295 300

Lys Asn Arg Met Ser Asn Leu Gln Val Lys Gln Arg Pro Lys Ser Ser
 305 310 315 320

Phe Leu Ala Asn Lys Gln Glu Arg Ser Ala Glu Asn Thr Ile Leu Pro
 325 330 335

Glu Glu Glu Thr Val Val Gln Asn Thr Ser Ala Gly Lys Asp Pro Leu

340	345	350
Lys Val Glu Asn Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe 355 360 365		
Thr Lys Arg Glu Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser 370 375 380		
Gly Lys Glu Ile Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn 385 390 395 400		
Phe Ile Tyr Asp Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His 405 410 415		
Tyr Ala Ser Gln Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu 420 425 430		
Glu Arg Ala Phe Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln 435 440 445		
Thr Gly Ser Gly Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro 450 455 460		
Gly Ile Ile Pro Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg 465 470 475 480		
Lys Gln Thr Gln Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu 485 490 495		
Val Tyr Asn Glu Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn 500 505 510		
Gly Gln Arg Lys Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly 515 520 525		
Pro Tyr Val Glu Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp 530 535 540		
Ile Gln Ser Trp Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala 545 550 555 560		
Thr Gly Met Asn Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu 565 570 575		
Val Met Thr Gln Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp 580 585 590		

His Arg Ile Thr Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu
 595 600 605

Arg Cys Ser Thr Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val
 610 615 620

Ser Ile Asn Lys Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu
 625 630 635 640

Ser Glu Gln Ala Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser
 645 650 655

Val Leu Thr Trp Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr
 660 665 670

Ala Met Ile Ala Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr
 675 680 685

Leu Ser Thr Leu Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile
 690 695 700

Ala Lys Val Asn Glu Asp Met Asn Ala Lys Leu Ile Arg Glu Leu Lys
 705 710 715 720

Ala Glu Ile Ala Lys Leu Lys Ala Ala Gln Arg Asn Ser Arg Asn Ile
 725 730 735

Asp Pro Glu Arg Tyr Arg Leu Cys Arg Gln Glu Ile Thr Ser Leu Arg
 740 745 750

Met Lys Leu His Gln Gln Glu Arg Asp Met Ala Glu Met Gln Arg Val
 755 760 765

Trp Lys Glu Lys Phe Glu Gln Ala Glu Lys Arg Lys Leu Gln Glu Thr
 770 775 780

Lys Glu Leu Gln Lys Ala Gly Ile Met Phe Gln Met Asp Asn His Leu
 785 790 795 800

Pro Asn Leu Val Asn Leu Asn Glu Asp Pro Gln Leu Ser Glu Met Leu
 805 810 815

Leu Tyr Met Ile Lys Glu Gly Thr Thr Thr Val Gly Lys Tyr Lys Pro
 820 825 830

Asn Ser Ser His Asp Ile Gln Leu Ser Gly Val Leu Ile Ala Asp Asp
 835 840 845

His Cys Thr Ile Lys Asn Phe Gly Gly Thr Val Ser Ile Ile Pro Val
 850 855 860

Gly Glu Ala Lys Thr Tyr Val Asn Gly Lys His Ile Leu Glu Ile Thr
 865 870 875 880

Val Leu Arg His Gly Asp Arg Val Ile Leu Gly Gly Asp His Tyr Phe
 885 890 895

Arg Phe Asn His Pro Val Glu Val Gln Lys Gly Lys Arg Pro Ser Gly
 900 905 910

Arg Asp Thr Pro Ile Ser Glu Gly Pro Lys Asp Phe Glu Phe Ala Lys
 915 920 925

Asn Glu Leu Leu Met Ala Gln Arg Ser Gln Leu Glu Ala Glu Ile Lys
 930 935 940

Glu Ala Gln Leu Lys Ala Lys Glu Glu Met Met Gln Gly Ile Gln Ile
 945 950 955 960

Ala Lys Glu Met Ala Gln Gln Glu Leu Ser Ser Gln Lys Ala Ala Tyr
 965 970 975

Glu Ser Lys Ile Lys Ala Leu Glu Ala Glu Leu Arg Glu Glu Ser Gln
 980 985 990

Arg Lys Lys Met Gln Glu Ile Asn Asn Gln Lys Ala Asn His Lys Ile
 995 1000 1005

Glu Glu Leu Glu Lys Ala Lys Gln His Leu Glu Gln Glu Ile Tyr
 1010 1015 1020

Val Asn Lys Lys Arg Leu Glu Met Glu Thr Leu Ala Thr Lys Gln
 1025 1030 1035

Ala Leu Glu Asp His Ser Ile Arg His Ala Arg Ile Leu Glu Ala
 1040 1045 1050

Leu Glu Thr Glu Lys Gln Lys Ile Ala Lys Glu Val Gln Ile Leu
 1055 1060 1065

Gln	Gln	Asn	Arg	Asn	Asn	Arg	Asp	Lys	Thr	Phe	Thr	Val	Gln	Thr
1070						1075					1080			
Thr	Trp	Ser	Ser	Met	Lys	Leu	Ser	Met	Met	Ile	Gln	Glu	Ala	Asn
1085						1090					1095			
Ala	Ile	Ser	Ser	Lys	Leu	Lys	Thr	Tyr	Tyr	Val	Phe	Gly	Arg	His
1100						1105					1110			
Asp	Ile	Ser	Asp	Lys	Ser	Ser	Ser	Asp	Thr	Ser	Ile	Arg	Val	Arg
1115						1120					1125			
Asn	Leu	Lys	Leu	Gly	Ile	Ser	Thr	Phe	Trp	Ser	Leu	Glu	Lys	Phe
1130						1135					1140			
Glu	Ser	Lys	Leu	Ala	Ala	Met	Lys	Glu	Leu	Tyr	Glu	Ser	Asn	Gly
1145						1150					1155			
Ser	Asn	Arg	Gly	Glu	Asp	Ala	Phe	Cys	Asp	Pro	Glu	Asp	Glu	Trp
1160						1165					1170			
Glu	Pro	Asp	Ile	Thr	Asp	Ala	Pro	Val	Ser	Ser	Leu	Ser	Arg	Arg
1175						1180					1185			
Arg	Ser	Arg	Ser	Leu	Met	Lys	Asn	Arg	Arg	Ile	Ser	Gly	Cys	Leu
1190						1195					1200			
His	Asp	Ile	Gln	Val	His	Pro	Ile	Lys	Asn	Leu	His	Ser	Ser	His
1205						1210					1215			
Ser	Ser	Gly	Leu	Met	Asp	Lys	Ser	Ser	Thr	Ile	Tyr	Ser	Asn	Ser
1220						1225					1230			
Ala	Glu	Ser	Phe	Leu	Pro	Gly	Ile	Cys	Lys	Glu	Leu	Ile	Gly	Ser
1235						1240					1245			
Ser	Leu	Asp	Phe	Phe	Gly	Gln	Ser	Tyr	Asp	Glu	Glu	Arg	Thr	Ile
1250						1255					1260			
Ala	Asp	Ser	Leu	Ile	Asn	Ser	Phe	Leu	Lys	Ile	Tyr	Asn	Gly	Leu
1265						1270					1275			
Phe	Ala	Ile	Ser	Lys	Ala	His	Glu	Glu	Gln	Asp	Glu	Glu	Ser	Gln
1280						1285					1290			
Asp	Asn	Leu	Phe	Ser	Ser	Asp	Arg	Ala	Ile	Gln	Ser	Leu	Thr	Ile

1295		1300		1305
Gln Thr Ala Cys Ala Phe Glu	Gln Leu Val Val Leu Met Lys His			
1310	1315		1320	
Trp Leu Ser Asp Leu Leu Pro	Cys Thr Asn Ile Ala Arg Leu Glu			
1325	1330		1335	
Asp Glu Leu Arg Gln Glu Val	Lys Lys Leu Gly Gly Tyr Leu Gln			
1340	1345		1350	
Leu Phe Leu Gln Gly Cys Cys	Leu Asp Ile Ser Ser Met Ile Lys			
1355	1360		1365	
Glu Ala Gln Lys Asn Ala Ile	Gln Ile Val Gln Gln Ala Val Lys			
1370	1375		1380	
Tyr Val Gly Gln Leu Ala Val	Leu Lys Gly Ser Lys Leu His Phe			
1385	1390		1395	
Leu Glu Asn Gly Asn Asn Lys	Ala Ala Ser Val Gln Glu Glu Phe			
1400	1405		1410	
Met Asp Ala Val Cys Asp Gly	Val Gly Leu Gly Met Lys Ile Leu			
1415	1420		1425	
Leu Asp Ser Gly Leu Glu Lys	Ala Lys Glu Leu Gln His Glu Leu			
1430	1435		1440	
Phe Arg Gln Cys Thr Lys Asn	Glu Val Thr Lys Glu Met Lys Thr			
1445	1450		1455	
Asn Ala Met Gly Leu Ile Arg	Ser Leu Glu Asn Ile Phe Ala Glu			
1460	1465		1470	
Ser Lys Ile Lys Ser Phe Arg	Arg Gln Val Gln Glu Glu Asn Phe			
1475	1480		1485	
Glu Tyr Gln Asp Phe Lys Arg	Met Val Asn Arg Ala Pro Glu Phe			
1490	1495		1500	
Leu Lys Leu Lys His Cys Leu	Glu Lys Ala Ile Glu Ile Ile Ile			
1505	1510		1515	
Ser Ala Leu Lys Gly Cys His	Ser Asp Ile Asn Leu Leu Gln Thr			
1520	1525		1530	

Cys Val Glu Ser Ile Arg Asn Leu Ala Ser Asp Phe Tyr Ser Asp
 1535 1540 1545

Phe Ser Val Pro Ser Thr Ser Val Gly Ser Tyr Glu Ser Arg Val
 1550 1555 1560

Thr His Ile Val His Gln Glu Leu Glu Ser Leu Ala Lys Ser Leu
 1565 1570 1575

Leu Phe Cys Phe Glu Ser Glu Glu Ser Pro Asp Leu Leu Lys Pro
 1580 1585 1590

Trp Glu Thr Tyr Asn Gln Asn Thr Lys Glu Glu His Gln Gln Ser
 1595 1600 1605

Lys Ser Ser Gly Ile Asp Gly Ser Lys Asn Lys Gly Val Pro Lys
 1610 1615 1620

Arg Val Tyr Glu Leu His Gly Ser Ser Pro Ala Val Ser Ser Glu
 1625 1630 1635

Glu Cys Thr Pro Ser Arg Ile Gln Trp Val
 1640 1645

<210> 3
 <211> 354
 <212> PRT
 <213> Homo Sapiens

<400> 3

Asn Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe Thr Lys Arg
 1 5 10 15

Glu Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser Gly Lys Glu
 20 25 30

Ile Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn Phe Ile Tyr
 35 40 45

Asp Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His Tyr Ala Ser
 50 55 60

Gln Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu Glu Arg Ala
 65 70 75 80

Phe Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln Thr Gly Ser
 85 90 95
 Gly Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro Gly Ile Ile
 100 105 110
 Pro Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg Lys Gln Thr
 115 120 125
 Gln Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu Val Tyr Asn
 130 135 140
 Glu Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn Gly Gln Arg
 145 150 155 160
 Lys Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly Pro Tyr Val
 165 170 175
 Glu Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp Ile Gln Ser
 180 185 190
 Trp Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala Thr Gly Met
 195 200 205
 Asn Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu Val Met Thr
 210 215 220
 Gln Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp His Arg Ile
 225 230 235 240
 Thr Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu Arg Cys Ser
 245 250 255
 Thr Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val Ser Ile Asn
 260 265 270
 Lys Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu Ser Glu Gln
 275 280 285
 Ala Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser Val Leu Thr
 290 295 300
 Trp Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr Ala Met Ile
 305 310 315 320
 Ala Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr Leu Ser Thr

325

330

335

Leu Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile Ala Lys Val
 340 345 350

Asn Glu

<210> 4
 <211> 388
 <212> PRT
 <213> Homo Sapiens

<400> 4

Met Val Gln Asn Thr Ser Ala Gly Lys Asp Pro Leu Lys Val Glu Asn
 1 5 10 15

Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe Thr Lys Arg Glu
 20 25 30

Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser Gly Lys Glu Ile
 35 40 45

Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn Phe Ile Tyr Asp
 50 55 60

Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His Tyr Ala Ser Gln
 65 70 75 80

Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu Glu Arg Ala Phe
 85 90 95

Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln Thr Gly Ser Gly
 100 105 110

Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro Gly Ile Ile Pro
 115 120 125

Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg Lys Gln Thr Gln
 130 135 140

Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu Val Tyr Asn Glu
 145 150 155 160

Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn Gly Gln Arg Lys
 165 170 175

Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly Pro Tyr Val Glu
 180 185 190
 Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp Ile Gln Ser Trp
 195 200 205
 Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala Thr Gly Met Asn
 210 215 220
 Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu Val Met Thr Gln
 225 230 235 240
 Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp His Arg Ile Thr
 245 250 255
 Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu Arg Cys Ser Thr
 260 265 270
 Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val Ser Ile Asn Lys
 275 280 285
 Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu Ser Glu Gln Ala
 290 295 300
 Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser Val Leu Thr Trp
 305 310 315 320
 Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr Ala Met Ile Ala
 325 330 335
 Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr Leu Ser Thr Leu
 340 345 350
 Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile Ala Lys Val Asn
 355 360 365
 Glu Asp Met Asn Ala Lys Leu Ile Arg Glu Leu Lys Leu Glu His His
 370 375 380
 His His His His
 385

<210> 5
 <211> 378
 <212> PRT
 <213> Homo Sapiens

<400> 5

Met Val Gln Asn Thr Ser Ala Gly Lys Asp Pro Leu Lys Val Glu Asn
 1 5 10 15

Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe Thr Lys Arg Glu
 20 25 30

Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser Gly Lys Glu Ile
 35 40 45

Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn Phe Ile Tyr Asp
 50 55 60

Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His Tyr Ala Ser Gln
 65 70 75 80

Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu Glu Arg Ala Phe
 85 90 95

Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln Thr Gly Ser Gly
 100 105 110

Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro Gly Ile Ile Pro
 115 120 125

Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg Lys Gln Thr Gln
 130 135 140

Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu Val Tyr Asn Glu
 145 150 155 160

Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn Gly Gln Arg Lys
 165 170 175

Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly Pro Tyr Val Glu
 180 185 190

Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp Ile Gln Ser Trp
 195 200 205

Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala Thr Gly Met Asn
 210 215 220

Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu Val Met Thr Gln
 225 230 235 240

Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp His Arg Ile Thr
 245 250 255

Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu Arg Cys Ser Thr
 260 265 270

Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val Ser Ile Asn Lys
 275 280 285

Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu Ser Glu Gln Ala
 290 295 300

Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser Val Leu Thr Trp
 305 310 315 320

Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr Ala Met Ile Ala
 325 330 335

Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr Leu Ser Thr Leu
 340 345 350

Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile Ala Lys Val Asn
 355 360 365

Glu Asp Leu Glu His His His His His His
 370 375

<210> 6
 <211> 376
 <212> PRT
 <213> Homo Sapiens

<400> 6

Met Val Glu Asn Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe
 1 5 10 15

Thr Lys Arg Glu Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser
 20 25 30

Gly Lys Glu Ile Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn
 35 40 45

Phe Ile Tyr Asp Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His
 50 55 60

Tyr Ala Ser Gln Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu
 65 70 75 80
 Glu Arg Ala Phe Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln
 85 90 95
 Thr Gly Ser Gly Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro
 100 105 110
 Gly Ile Ile Pro Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg
 115 120 125
 Lys Gln Thr Gln Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu
 130 135 140
 Val Tyr Asn Glu Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn
 145 150 155 160
 Gly Gln Arg Lys Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly
 165 170 175
 Pro Tyr Val Glu Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp
 180 185 190
 Ile Gln Ser Trp Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala
 195 200 205
 Thr Gly Met Asn Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu
 210 215 220
 Val Met Thr Gln Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp
 225 230 235 240
 His Arg Ile Thr Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu
 245 250 255
 Arg Cys Ser Thr Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val
 260 265 270
 Ser Ile Asn Lys Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu
 275 280 285
 Ser Glu Gln Ala Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser
 290 295 300
 Val Leu Thr Trp Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr

305 310 315 320
 Ala Met Ile Ala Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr
 325 330 335
 Leu Ser Thr Leu Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile
 340 345 350
 Ala Lys Val Asn Glu Asp Met Asn Ala Lys Leu Ile Arg Glu Leu Lys
 355 360 365
 Leu Glu His His His His His His
 370 375

 <210> 7
 <211> 366
 <212> PRT
 <213> Homo Sapiens

 <400> 7
 Met Val Glu Asn Ser Gln Val Thr Val Ala Val Arg Val Arg Pro Phe
 1 5 10 15
 Thr Lys Arg Glu Lys Ile Glu Lys Ala Ser Gln Val Val Phe Met Ser
 20 25 30
 Gly Lys Glu Ile Thr Val Glu His Pro Asp Thr Lys Gln Val Tyr Asn
 35 40 45
 Phe Ile Tyr Asp Val Ser Phe Trp Ser Phe Asp Glu Cys His Pro His
 50 55 60
 Tyr Ala Ser Gln Thr Thr Val Tyr Glu Lys Leu Ala Ala Pro Leu Leu
 65 70 75 80
 Glu Arg Ala Phe Glu Gly Phe Asn Thr Cys Leu Phe Ala Tyr Gly Gln
 85 90 95
 Thr Gly Ser Gly Lys Ser Tyr Thr Met Met Gly Phe Ser Glu Glu Pro
 100 105 110
 Gly Ile Ile Pro Arg Phe Cys Glu Asp Leu Phe Ser Gln Val Ala Arg
 115 120 125
 Lys Gln Thr Gln Glu Val Ser Tyr His Ile Glu Met Ser Phe Phe Glu
 130 135 140

Val Tyr Asn Glu Lys Ile His Asp Leu Leu Val Cys Lys Asp Glu Asn
 145 150 155 160
 Gly Gln Arg Lys Gln Pro Leu Arg Val Arg Glu His Pro Val Tyr Gly
 165 170 175
 Pro Tyr Val Glu Ala Leu Ser Met Asn Ile Val Ser Ser Tyr Ala Asp
 180 185 190
 Ile Gln Ser Trp Leu Glu Leu Gly Asn Lys Gln Arg Ala Thr Ala Ala
 195 200 205
 Thr Gly Met Asn Asp Lys Ser Ser Arg Ser His Ser Val Phe Thr Leu
 210 215 220
 Val Met Thr Gln Thr Lys Thr Glu Phe Val Glu Gly Glu Glu His Asp
 225 230 235 240
 His Arg Ile Thr Ser Arg Ile Asn Leu Ile Asp Leu Ala Gly Ser Glu
 245 250 255
 Arg Cys Ser Thr Ala His Thr Asn Gly Asp Arg Leu Lys Glu Gly Val
 260 265 270
 Ser Ile Asn Lys Ser Leu Leu Thr Leu Gly Lys Val Ile Ser Ala Leu
 275 280 285
 Ser Glu Gln Ala Asn Gln Arg Ser Val Phe Ile Pro Tyr Arg Glu Ser
 290 295 300
 Val Leu Thr Trp Leu Leu Lys Glu Ser Leu Gly Gly Asn Ser Lys Thr
 305 310 315 320
 Ala Met Ile Ala Thr Ile Ser Pro Ala Ala Ser Asn Ile Glu Glu Thr
 325 330 335
 Leu Ser Thr Leu Arg Tyr Ala Asn Gln Ala Arg Leu Ile Val Asn Ile
 340 345 350
 Ala Lys Val Asn Glu Asp Leu Glu His His His His His His
 355 360 365

<210> 8
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
<223> siRNA

<220>
<221> misc_feature
<222> (1)..(21)
<223> double stranded

<220>
<221> misc_feature
<222> (20)..(21)
<223> N = DNA (T)

<400> 8
aaacugggag gcuacuuacn n 21

<210> 9
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA

<220>
<221> misc_feature
<222> (1)..(21)
<223> double stranded

<220>
<221> misc_feature
<222> (20)..(21)
<223> N = DNA (T)

<400> 9
cucacauugu ccaccaggan n 21

<210> 10
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA

<220>
<221> misc_feature
<222> (1)..(21)
<223> double stranded

<220>
<221> misc_feature
<222> (20)..(21)
<223> N = DNA (T)

<400> 10
cguacgcgga auacuucgan n 21

<210> 11
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> single stranded DNA

<220>
<221> misc_feature
<222> (1)..(31)
<223> Primer 1

<400> 11
gtctagacat atggttcaga acacctctgc a

31

<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> single stranded DNA

<220>
<221> misc_feature
<222> (1)..(30)
<223> Primer 2

<400> 12
tgcctcgagc ttcaattctc taattaactt

30

<210> 13
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> single stranded DNA

<220>
<221> misc_feature
<222> (1)..(31)
<223> Primer 3

<400> 13
gtctagacat atggtagaga atagtcaagt g

31

<210> 14
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> single stranded DNA

<220>

<221> misc_feature

<222> (1)..(30)

<223> Primer 4

<400> 14

tgccctcgaga tcttcattta ctttagcaat

30

<210> 15

<211> 373

<212> PRT

<213> Homo Sapiens

<400> 15

Met Ala Ser Gln Pro Asn Ser Ser Ala Lys Lys Lys Glu Glu Lys Gly
1 5 10 15

Lys Asn Ile Gln Val Val Val Arg Cys Arg Pro Phe Asn Leu Ala Glu
20 25 30

Arg Lys Ala Ser Ala His Ser Ile Val Glu Cys Asp Pro Val Arg Lys
35 40 45

Glu Val Ser Val Arg Thr Gly Gly Leu Ala Asp Lys Ser Ser Arg Lys
50 55 60

Thr Tyr Thr Phe Asp Met Val Phe Gly Ala Ser Thr Lys Gln Ile Asp
65 70 75 80

Val Tyr Arg Ser Val Val Cys Pro Ile Leu Asp Glu Val Ile Met Gly
85 90 95

Tyr Asn Cys Thr Ile Phe Ala Tyr Gly Gln Thr Gly Thr Gly Lys Thr
100 105 110

Phe Thr Met Glu Gly Glu Arg Ser Pro Asn Glu Glu Tyr Thr Trp Glu
115 120 125

Glu Asp Pro Leu Ala Gly Ile Ile Pro Arg Thr Leu His Gln Ile Phe
130 135 140

Glu Lys Leu Thr Asp Asn Gly Thr Glu Phe Ser Val Lys Val Ser Leu
145 150 155 160

Leu Glu Ile Tyr Asn Glu Glu Leu Phe Asp Leu Leu Asn Pro Ser Ser
165 170 175

Asp Val Ser Glu Arg Leu Gln Met Phe Asp Asp Pro Arg Asn Lys Arg
 180 185 190

Gly Val Ile Ile Lys Gly Leu Glu Glu Ile Thr Val His Asn Lys Asp
 195 200 205

Glu Val Tyr Gln Ile Leu Glu Lys Gly Ala Ala Lys Arg Thr Thr Ala
 210 215 220

Ala Thr Leu Met Asn Ala Tyr Ser Ser Arg Ser His Ser Val Phe Ser
 225 230 235 240

Val Thr Ile His Met Lys Glu Thr Thr Ile Asp Gly Glu Glu Leu Val
 245 250 255

Lys Ile Gly Lys Leu Asn Leu Val Asp Leu Ala Gly Ser Glu Asn Ile
 260 265 270

Gly Arg Ser Gly Ala Val Asp Lys Arg Ala Arg Glu Ala Gly Asn Ile
 275 280 285

Asn Gln Ser Leu Leu Thr Leu Gly Arg Val Ile Thr Ala Leu Val Glu
 290 295 300

Arg Thr Pro His Val Pro Tyr Arg Glu Ser Lys Leu Thr Arg Ile Leu
 305 310 315 320

Gln Asp Ser Leu Gly Gly Arg Thr Arg Thr Ser Ile Ile Ala Thr Ile
 325 330 335

Ser Pro Ala Ser Leu Asn Leu Glu Glu Thr Leu Ser Thr Leu Glu Tyr
 340 345 350

Ala His Arg Ala Lys Asn Ile Leu Asn Lys Pro Glu Val Asn Gln His
 355 360 365

His His His His His
 370

<210> 16
 <211> 365
 <212> PRT
 <213> Homo Sapiens

<400> 16

Met Pro Ile Asn Lys Ser Glu Lys Pro Glu Ser Cys Asp Asn Val Lys
 1 5 10 15
 Val Val Val Arg Cys Arg Pro Leu Asn Glu Arg Glu Lys Ser Met Cys
 20 25 30
 Tyr Lys Gln Ala Val Ser Val Asp Glu Met Arg Gly Thr Ile Thr Val
 35 40 45
 His Lys Thr Asp Ser Ser Asn Glu Pro Pro Lys Thr Phe Thr Phe Asp
 50 55 60
 Thr Val Phe Gly Pro Glu Ser Lys Gln Leu Asp Val Tyr Asn Leu Thr
 65 70 75 80
 Ala Arg Pro Ile Ile Asp Ser Val Leu Glu Gly Tyr Asn Gly Thr Ile
 85 90 95
 Phe Ala Tyr Gly Gln Thr Gly Thr Gly Lys Thr Phe Thr Met Glu Gly
 100 105 110
 Val Arg Ala Ile Pro Glu Leu Arg Gly Ile Ile Pro Asn Ser Phe Ala
 115 120 125
 His Ile Phe Gly His Ile Ala Lys Ala Glu Gly Asp Thr Arg Phe Leu
 130 135 140
 Val Arg Val Ser Tyr Leu Glu Ile Tyr Asn Glu Glu Val Arg Asp Leu
 145 150 155 160
 Leu Gly Lys Asp Gln Thr Gln Arg Leu Glu Val Lys Glu Arg Pro Asp
 165 170 175
 Val Gly Val Tyr Ile Lys Asp Leu Ser Ala Tyr Val Val Asn Asn Ala
 180 185 190
 Asp Asp Met Asp Arg Ile Met Thr Leu Gly His Lys Asn Arg Ser Val
 195 200 205
 Gly Ala Thr Asn Met Asn Glu His Ser Ser Arg Ser His Ala Ile Phe
 210 215 220
 Thr Ile Thr Ile Glu Cys Ser Glu Lys Gly Ile Asp Gly Asn Met His
 225 230 235 240
 Val Arg Met Gly Lys Leu His Leu Val Asp Leu Ala Gly Ser Glu Arg

30

Gly Lys Leu His Asp Pro Glu Gly Met Gly Ile Ile Pro Arg Ile Val
 100 105 110

Gln Asp Ile Phe Asn Tyr Ile Tyr Ser Met Asp Glu Asn Leu Glu Phe
 115 120 125

His Ile Lys Val Ser Tyr Phe Glu Ile Tyr Leu Asp Lys Ile Arg Asp
 130 135 140

Leu Leu Asp Val Ser Lys Thr Asn Leu Ser Val His Glu Asp Lys Asn
 145 150 155 160

Arg Val Pro Tyr Val Lys Gly Cys Thr Glu Arg Phe Val Cys Ser Pro
 165 170 175

Asp Glu Val Met Asp Thr Ile Asp Glu Gly Lys Ser Asn Arg His Val
 180 185 190

Ala Val Thr Asn Met Asn Glu His Ser Ser Arg Ser His Ser Ile Phe
 195 200 205

Leu Ile Asn Val Lys Gln Glu Asn Thr Gln Thr Glu Gln Lys Leu Ser
 210 215 220

Gly Lys Leu Tyr Leu Val Asp Leu Ala Gly Ser Glu Lys Val Ser Lys
 225 230 235 240

Thr Gly Ala Glu Gly Ala Val Leu Asp Glu Ala Lys Asn Ile Asn Lys
 245 250 255

Ser Leu Ser Ala Leu Gly Asn Val Ile Ser Ala Leu Ala Glu Gly Ser
 260 265 270

Thr Tyr Val Pro Tyr Arg Asp Ser Lys Met Thr Arg Ile Leu Gln Asp
 275 280 285

Ser Leu Gly Gly Asn Cys Arg Thr Thr Ile Val Ile Cys Cys Ser Pro
 290 295 300

Ser Ser Tyr Asn Glu Ser Glu Thr Lys Ser Thr Leu Leu Phe Gly Gln
 305 310 315 320

Arg Ala Lys Thr Ile Lys Asn Thr Val Cys Val Asn Val Glu Leu Thr
 325 330 335

Ala Val Asp Lys Leu Ala Ala Ala Leu Glu His His His His His His
 340 345 350

<210> 18
 <211> 355
 <212> PRT
 <213> Homo Sapiens

<400> 18

Met Ala Glu Thr Asn Asn Glu Cys Ser Ile Lys Val Leu Cys Arg Phe
 1 5 10 15

Arg Pro Leu Asn Gln Ala Glu Ile Leu Arg Gly Asp Lys Phe Ile Pro
 20 25 30

Ile Phe Gln Gly Asp Asp Ser Val Val Ile Gly Gly Lys Pro Tyr Val
 35 40 45

Phe Asp Arg Val Phe Pro Pro Asn Thr Thr Gln Glu Gln Val Tyr His
 50 55 60

Ala Cys Ala Met Gln Ile Val Lys Asp Val Leu Ala Gly Tyr Asn Gly
 65 70 75 80

Thr Ile Phe Ala Tyr Gly Gln Thr Ser Ser Gly Lys Thr His Thr Met
 85 90 95

Glu Gly Lys Leu His Asp Pro Gln Leu Met Gly Ile Ile Pro Arg Ile
 100 105 110

Ala Arg Asp Ile Phe Asn His Ile Tyr Ser Met Asp Glu Asn Leu Glu
 115 120 125

Phe His Ile Lys Val Ser Tyr Phe Glu Ile Tyr Leu Asp Lys Ile Arg
 130 135 140

Asp Leu Leu Asp Val Thr Lys Thr Asn Leu Ser Val His Glu Asp Lys
 145 150 155 160

Asn Arg Val Pro Phe Val Lys Gly Cys Thr Glu Arg Phe Val Ser Ser
 165 170 175

Pro Glu Glu Ile Leu Asp Val Ile Asp Glu Gly Lys Ser Asn Arg His
 180 185 190

Val Ala Val Thr Asn Met Asn Glu His Ser Ser Arg Ser His Ser Ile
 195 200 205

Phe Leu Ile Asn Ile Lys Gln Glu Asn Met Glu Thr Glu Gln Lys Leu
 210 215 220

Ser Gly Lys Leu Tyr Leu Val Asp Leu Ala Gly Ser Glu Lys Val Ser
 225 230 235 240

Lys Thr Gly Ala Glu Gly Ala Val Leu Asp Glu Ala Lys Asn Ile Asn
 245 250 255

Lys Ser Leu Ser Ala Leu Gly Asn Val Ile Ser Ala Leu Ala Glu Gly
 260 265 270

Thr Lys Ser Tyr Val Pro Tyr Arg Asp Ser Lys Met Thr Arg Ile Leu
 275 280 285

Gln Asp Ser Leu Gly Gly Asn Cys Arg Thr Thr Met Phe Ile Cys Cys
 290 295 300

Ser Pro Ser Ser Tyr Asn Asp Ala Glu Thr Lys Ser Thr Leu Met Phe
 305 310 315 320

Gly Gln Arg Ala Lys Thr Ile Lys Asn Thr Ala Ser Val Asn Leu Glu
 325 330 335

Leu Thr Ala Glu Val Asp Lys Leu Ala Ala Ala Leu Glu His His His
 340 345 350

His His His
 355

<210> 19
 <211> 355
 <212> PRT
 <213> Homo Sapiens

<400> 19

Met Ala Glu Glu Gly Ala Val Ala Val Cys Val Arg Val Arg Pro Leu
 1 5 10 15

Asn Ser Arg Glu Glu Ser Leu Gly Glu Thr Ala Gln Val Tyr Trp Lys
 20 25 30

Thr Asp Asn Asn Val Ile Tyr Gln Val Asp Gly Ser Lys Ser Phe Asn
 35 40 45

Phe Asp Arg Val Phe His Gly Asn Glu Thr Thr Lys Asn Val Tyr Glu
50 55 60

Glu Ile Ala Ala Pro Ile Ile Asp Ser Ala Ile Gln Gly Tyr Asn Gly
65 70 75 80

Thr Ile Phe Ala Tyr Gly Gln Thr Ala Ser Gly Lys Thr Tyr Thr Met
85 90 95

Met Gly Ser Glu Asp His Leu Gly Val Ile Pro Arg Ala Ile His Asp
100 105 110

Ile Phe Gln Lys Ile Lys Lys Phe Pro Asp Arg Glu Phe Leu Leu Arg
115 120 125

Val Ser Tyr Met Glu Ile Tyr Asn Glu Thr Ile Thr Asp Leu Leu Cys
130 135 140

Gly Thr Gln Lys Met Lys Pro Leu Ile Ile Arg Glu Asp Val Asn Arg
145 150 155 160

Asn Val Tyr Val Ala Asp Leu Thr Glu Glu Val Val Tyr Thr Ser Glu
165 170 175

Met Ala Leu Lys Trp Ile Thr Lys Gly Glu Lys Ser Arg His Tyr Gly
180 185 190

Glu Thr Lys Met Asn Gln Arg Ser Ser Arg Ser His Thr Ile Phe Arg
195 200 205

Met Ile Leu Glu Ser Arg Glu Lys Gly Glu Pro Ser Asn Cys Glu Gly
210 215 220

Ser Val Lys Val Ser His Leu Asn Leu Val Asp Leu Ala Gly Ser Glu
225 230 235 240

Arg Ala Ala Gln Thr Gly Ala Ala Gly Val Arg Leu Lys Glu Gly Cys
245 250 255

Asn Ile Asn Arg Ser Leu Phe Ile Leu Gly Gln Val Ile Lys Lys Leu
260 265 270

Ser Asp Gly Gln Val Gly Gly Phe Ile Asn Tyr Arg Asp Ser Lys Leu
275 280 285

Thr Arg Ile Leu Gln Asn Ser Leu Gly Gly Asn Ala Lys Thr Arg Ile

290

295

300

Ile Cys Thr Ile Thr Pro Val Ser Phe Asp Glu Thr Leu Thr Ala Leu
 305 310 315 320

Gln Phe Ala Ser Thr Ala Lys Tyr Met Lys Asn Thr Pro Tyr Val Asn
 325 330 335

Glu Val Ser Thr Val Asp Lys Leu Ala Ala Ala Leu Glu His His His
 340 345 350

His His His
 355

<210> 20
 <211> 448
 <212> PRT
 <213> Homo Sapiens

<400> 20

Met Ala Arg Ala Lys Thr Pro Arg Lys Pro Thr Val Lys Lys Gly Ser
 1 5 10 15

Gln Thr Asn Leu Lys Asp Pro Val Gly Val Tyr Cys Arg Val Arg Pro
 20 25 30

Leu Gly Phe Pro Asp Gln Glu Cys Cys Ile Glu Val Ile Asn Asn Thr
 35 40 45

Thr Val Gln Leu His Thr Pro Glu Gly Tyr Arg Leu Asn Arg Asn Gly
 50 55 60

Asp Tyr Lys Glu Thr Gln Tyr Ser Phe Lys Gln Val Phe Gly Thr His
 65 70 75 80

Thr Thr Gln Lys Glu Leu Phe Asp Val Val Ala Asn Pro Leu Val Asn
 85 90 95

Asp Leu Ile His Gly Lys Asn Gly Leu Leu Phe Thr Tyr Gly Val Thr
 100 105 110

Gly Ser Gly Lys Thr His Thr Met Thr Gly Ser Pro Gly Glu Gly Gly
 115 120 125

Leu Leu Pro Arg Cys Leu Asp Met Ile Phe Asn Ser Ile Gly Ser Phe
 130 135 140

Gln Ala Lys Arg Tyr Val Phe Lys Ser Asn Asp Arg Asn Ser Met Asp
 145 150 155 160

Ile Gln Cys Glu Val Asp Ala Leu Leu Glu Arg Gln Lys Arg Glu Ala
 165 170 175

Met Pro Asn Pro Lys Thr Ser Ser Ser Lys Arg Gln Val Asp Pro Glu
 180 185 190

Phe Ala Asp Met Ile Thr Val Gln Glu Phe Cys Lys Ala Glu Glu Val
 195 200 205

Asp Glu Asp Ser Val Tyr Gly Val Phe Val Ser Tyr Ile Glu Ile Tyr
 210 215 220

Asn Asn Tyr Ile Tyr Asp Leu Leu Glu Glu Val Pro Phe Asp Pro Ile
 225 230 235 240

Lys Pro Lys Pro Pro Gln Ser Lys Leu Leu Arg Glu Asp Lys Asn His
 245 250 255

Asn Met Tyr Val Ala Gly Cys Thr Glu Val Glu Val Lys Ser Thr Glu
 260 265 270

Glu Ala Phe Glu Val Phe Trp Arg Gly Gln Lys Lys Arg Arg Ile Ala
 275 280 285

Asn Thr His Leu Asn Arg Glu Ser Ser Arg Ser His Ser Val Phe Asn
 290 295 300

Ile Lys Leu Val Gln Ala Pro Leu Asp Ala Asp Gly Asp Asn Val Leu
 305 310 315 320

Gln Glu Lys Glu Gln Ile Thr Ile Ser Gln Leu Ser Leu Val Asp Leu
 325 330 335

Ala Gly Ser Glu Arg Thr Asn Arg Thr Arg Ala Glu Gly Asn Arg Leu
 340 345 350

Arg Glu Ala Gly Asn Ile Asn Gln Ser Leu Met Thr Leu Arg Thr Cys
 355 360 365

Met Asp Val Leu Arg Glu Asn Gln Met Tyr Gly Thr Asn Lys Met Val
 370 375 380

Pro Tyr Arg Asp Ser Lys Leu Thr His Leu Phe Lys Asn Tyr Phe Asp
385 390 395 400

Gly Glu Gly Lys Val Arg Met Ile Val Cys Val Asn Pro Lys Ala Glu
405 410 415

Asp Tyr Glu Glu Asn Leu Gln Val Met Arg Phe Ala Glu Val Thr Gln
420 425 430

Glu Val Asp Lys Leu Ala Ala Ala Leu Glu His His His His His His
435 440 445

<210> 21

<211> 365

<212> PRT

<213> Homo Sapiens

<400> 21

Met Ser Gly Ala Ser Val Lys Val Ala Val Arg Val Arg Pro Phe Asn
1 5 10 15

Ser Arg Glu Thr Ser Lys Glu Ser Lys Cys Ile Ile Gln Met Gln Gly
20 25 30

Asn Ser Thr Ser Ile Ile Asn Pro Lys Asn Pro Lys Glu Ala Pro Lys
35 40 45

Ser Phe Ser Phe Asp Tyr Ser Tyr Trp Ser His Thr Ser Pro Glu Asp
50 55 60

Pro Cys Phe Ala Ser Gln Asn Arg Val Tyr Asn Asp Ile Gly Lys Glu
65 70 75 80

Met Leu Leu His Ala Phe Glu Gly Tyr Asn Val Cys Ile Phe Ala Tyr
85 90 95

Gly Gln Thr Gly Ala Gly Lys Ser Tyr Thr Met Met Gly Lys Gln Glu
100 105 110

Glu Ser Gln Ala Gly Ile Ile Pro Gln Leu Cys Glu Glu Leu Phe Glu
115 120 125

Lys Ile Asn Asp Asn Cys Asn Glu Glu Met Ser Tyr Ser Val Glu Val
130 135 140

Ser Tyr Met Glu Ile Tyr Cys Glu Arg Val Arg Asp Leu Leu Asn Pro
145 150 155 160

Lys Asn Lys Gly Asn Leu Arg Val Arg Glu His Pro Leu Leu Gly Pro
 165 170 175

Tyr Val Glu Asp Leu Ser Lys Leu Ala Val Thr Ser Tyr Thr Asp Ile
 180 185 190

Ala Asp Leu Met Asp Ala Gly Asn Lys Ala Arg Thr Val Ala Ala Thr
 195 200 205

Asn Met Asn Glu Thr Ser Ser Arg Ser His Ala Val Phe Thr Ile Val
 210 215 220

Phe Thr Gln Lys Lys His Asp Asn Glu Thr Asn Leu Ser Thr Glu Lys
 225 230 235 240

Val Ser Lys Ile Ser Leu Val Asp Leu Ala Gly Ser Glu Arg Ala Asp
 245 250 255

Ser Thr Gly Ala Lys Gly Thr Arg Leu Lys Glu Gly Ala Asn Ile Asn
 260 265 270

Lys Ser Leu Thr Thr Leu Gly Lys Val Ile Ser Ala Leu Ala Glu Val
 275 280 285

Asp Asn Cys Thr Ser Lys Ser Lys Lys Lys Lys Lys Thr Asp Phe Ile
 290 295 300

Pro Tyr Arg Asp Ser Val Leu Thr Trp Leu Leu Arg Glu Asn Leu Gly
 305 310 315 320

Gly Asn Ser Arg Thr Ala Met Val Ala Ala Leu Ser Pro Ala Asp Ile
 325 330 335

Asn Tyr Asp Glu Thr Leu Ser Thr Leu Arg Tyr Ala Asp Arg Val Asp
 340 345 350

Lys Leu Ala Ala Ala Leu Glu His His His His His His
 355 360 365

<210> 22
 <211> 464
 <212> PRT
 <213> Homo Sapiens

<400> 22

Asn Pro Val Asn Ser Val Arg Arg Lys Ser Cys Leu Val Lys Glu Val
 1 5 10 15
 Glu Lys Met Lys Asn Lys Arg Glu Glu Lys Lys Ala Gln Asn Ser Glu
 20 25 30
 Met Arg Met Lys Arg Ala Gln Glu Tyr Asp Ser Ser Phe Pro Asn Trp
 35 40 45
 Glu Phe Ala Arg Met Ile Lys Glu Phe Arg Ala Thr Leu Glu Cys His
 50 55 60
 Pro Leu Thr Met Thr Asp Pro Ile Glu Glu His Arg Ile Cys Val Cys
 65 70 75 80
 Val Arg Lys Arg Pro Leu Asn Lys Gln Glu Leu Ala Lys Lys Glu Ile
 85 90 95
 Asp Val Ile Ser Ile Pro Ser Lys Cys Leu Leu Leu Val His Glu Pro
 100 105 110
 Lys Leu Lys Val Asp Leu Thr Lys Tyr Leu Glu Asn Gln Ala Phe Cys
 115 120 125
 Phe Asp Phe Ala Phe Asp Glu Thr Ala Ser Asn Glu Val Val Tyr Arg
 130 135 140
 Phe Thr Ala Arg Pro Leu Val Gln Thr Ile Phe Glu Gly Gly Lys Ala
 145 150 155 160
 Thr Cys Phe Ala Tyr Gly Gln Thr Gly Ser Gly Lys Thr His Thr Met
 165 170 175
 Gly Gly Asp Leu Ser Gly Lys Ala Gln Asn Ala Ser Lys Gly Ile Tyr
 180 185 190
 Ala Met Ala Ser Arg Asp Val Phe Leu Leu Lys Asn Gln Pro Cys Tyr
 195 200 205
 Arg Lys Leu Gly Leu Glu Val Tyr Val Thr Phe Phe Glu Ile Tyr Asn
 210 215 220
 Gly Lys Leu Phe Asp Leu Leu Asn Lys Lys Ala Lys Leu Arg Val Leu
 225 230 235 240
 Glu Asp Gly Lys Gln Gln Val Gln Val Val Gly Leu Gln Glu His Leu

	245		250		255
Val Asn Ser Ala Asp Asp Val Ile Lys Met Ile Asp Met Gly Ser Ala					
	260		265		270
Cys Arg Thr Ser Gly Gln Thr Phe Ala Asn Ser Asn Ser Ser Arg Ser					
	275		280		285
His Ala Cys Phe Gln Ile Ile Leu Arg Ala Lys Gly Arg Met His Gly					
	290		295		300
Lys Phe Ser Leu Val Asp Leu Ala Gly Asn Glu Arg Gly Ala Asp Thr					
	305		310		320
Ser Ser Ala Asp Arg Gln Thr Arg Met Glu Gly Ala Glu Ile Asn Lys					
	325		330		335
Ser Leu Leu Ala Leu Lys Glu Cys Ile Arg Ala Leu Gly Gln Asn Lys					
	340		345		350
Ala His Thr Pro Phe Arg Glu Ser Lys Leu Thr Gln Val Leu Arg Asp					
	355		360		365
Ser Phe Ile Gly Glu Asn Ser Arg Thr Cys Met Ile Ala Thr Ile Ser					
	370		375		380
Pro Gly Ile Ser Ser Cys Glu Tyr Thr Leu Asn Thr Leu Arg Tyr Ala					
	385		390		400
Asp Arg Val Lys Glu Leu Ser Pro His Ser Gly Pro Ser Gly Glu Gln					
	405		410		415
Leu Ile Gln Met Glu Thr Glu Glu Met Glu Ala Cys Ser Asn Gly Ala					
	420		425		430
Leu Ile Pro Gly Asn Leu Ser Lys Glu Glu Glu Glu Leu Ser Ser Gln					
	435		440		445
Met Ser Ser Phe Asn Glu Ala Met Thr Gln Ile Arg Glu Leu Glu Glu					
	450		455		460
<210> 23					
<211> 21					
<212> RNA					
<213> Artificial Sequence					
<220>					

<223> siRNA

<220>

<221> misc_feature

<222> (1)..(21)

<223> double stranded

<220>

<221> misc_feature

<222> (20)..(21)

<223> N = DNA (T)

<400> 23

guuggcuaga auugggaaan n

21

<210> 24

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> siRNA

<220>

<221> misc_feature

<222> (1)..(21)

<223> double stranded

<220>

<221> misc_feature

<222> (20)..(21)

<223> N = DNA (T)

<400> 24

ggacaacugc agcuacucun n

21